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The majority of evidence used by the World Health Organization (WHO) to inform 
guidelines for the treatment of multidrug-resistant tuberculosis (MDR-TB) is based on 
findings from observational cohort studies. Observational cohort studies have important 
limitations when interpreting estimates as causal effects, in contrast to randomized 
controlled trials (RCTs), the gold standard for assessing efficacy. Specifically, 
observational cohort studies are at greater risk of common threats to validity, such as 
selection bias and confounding. The consequences of residual bias in observational 
cohort studies of MDR-TB patients would be substantial, given WHO guidelines inform 
the treatment approach for the 500,000 patients estimated to fall sick with MDR-TB 
globally each year.  
The goals of this dissertation are to: assess the comparative effectiveness of adding 
delamanid to MDR-TB regimens (Aim 1), scrutinize the potential for selection bias when 
using different approaches to defining the subcohort of MDR-TB patients eligible for 
studies using sputum culture conversion outcomes (Aim 2), and evaluate differences in 
the interpretation and estimates of the comparative effectiveness of adding delamanid (as 
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explored in Aim 1) when the time-varying nature of MDR-TB treatment is and is not 
accounted for (Aim 3). 
In all aims, we use data from the observational cohort of the endTB initiative. The 
endTB initiative was launched in 2015 to rapidly expand access to two new drugs for 
MDR-TB, bedaquiline and delamanid, for over 2,700 patients in 17 countries. In 
partnership with national TB programs, a consortium of non-governmental organizations 
leads the initiative: Partners In Health, Médecins Sans Frontières, and Interactive 
Research and Development. Participants are treated in accordance with guidelines of 
WHO and their respective countries under routine programmatic conditions. Study 
activities are directed by a common protocol, data are collected using standardized forms, 
and adverse events (AE) are monitored through a unified pharmacovigilance system, 
which facilitates data consistency across sites. 
In Aim 1, we investigate whether adding delamanid to MDR-TB regimens comprised 
of three drugs likely to be effective improves two- and six-month culture conversion. We 
apply a censoring approach using inverse probability weighting that accounts for MDR-
TB regimen changes over the course of treatment to estimate the observational analogue 
of the per-protocol effect. We did not identify a difference in two- or six-month culture 
conversion between participants with delamanid added to their regimen and participants 
without delamanid. We hypothesize that delamanid did not provide a contribution to 
effectiveness because regimens already contained multiple efficacious drugs (e.g. 
linezolid, moxifloxacin/levofloxacin, bedaquiline). 
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In Aim 2, we used simulated data and data from the endTB observational cohort to 
evaluate whether extending the allowable baseline sputum culture collection interval past 
treatment initiation is a source of selection bias in studies using culture conversion 
outcomes. Two of the most influential factors that increased bias were the proportion of 
the cohort with a missing pre-treatment culture and the occurrence of death and loss to 
follow up (LTFU) in this group. These occurred infrequently in the endTB observational 
cohort; thus we did not observe meaningful differences when the baseline culture 
definition was extended past treatment initiation. In cohorts with an excess of missing 
pre-treatment culture data and early non-conversion events such as death and LTFU, 
extending the allowable interval past treatment initiation may introduce bias. 
Investigators should scrutinize whether extending the baseline sputum culture collection 
interval will inadvertently exclude these patients who may have been eligible for 
inclusion had they had pre-treatment sputum culture data. 
In Aim 3, we used the clinical research question from Aim 1 to investigate whether 
implementing inverse probability of censoring weights to account for the time-varying 
nature of MDR-TB treatment generated results that were different from those generated 
through baseline-adjusted analytic approaches. Results were similar using the two types 
of approaches. This similarity is likely a consequence of the relative modest frequency of 
regimen changes and the distribution of participants with regimen changes across 
exposure groups and the outcome. We hypothesize that estimates may differ 
meaningfully for research questions where treatment changes are highly concentrated in 
one exposure group and these treatment changes are highly associated with the outcome.  
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An estimated 10 million people globally developed tuberculosis (TB) disease in 2019.(1) 
Of these, nearly 500,000 harbored isolates resistant to at least rifampin (rifampin resistant 
TB, RR-TB), or rifampin and isoniazid (multidrug-resistant TB, MDR-TB), the most 
effective drugs to treat TB.(1) Conventional treatment for MDR-TB is complex and 
difficult. Patients must take a regimen of at least four drugs in which the probability of 
resistance is low (termed “likely effective” drugs).(2) Many of these drugs result in 
debilitating side effects such as peripheral neuropathy and permanent hearing loss.(3,4) 
Conventional treatment for MDR-TB is also long, lasting up to 24 months.(5) Even after 
enduring extensive and toxic treatment, outcomes are often poor: only half of patients 
reach bacteriologic cure (i.e., sputum culture conversion) or complete treatment.(6) 
Outcomes are worse for patients whose infecting strains harbor additional resistance to 
fluoroquinolones and injectable agents (historically classified as extensively drug 
resistant TB, XDR-TB); only one-third of patients have a successful treatment 
outcome.(6)  
The introduction of bedaquiline and delamanid—the first drugs with novel mechanisms 
of action against M. tuberculosis (M.tb) in nearly 50 years—have offered the potential to 
improve treatment for MDR-TB. Between 2012 and 2014, the United States (US) Food 
and Drug Administration and the European Medicines Agency approved bedaquiline and 
the European Medicines Agency approved delamanid for TB.(7,8) Recently, the WHO 
issued guidance revisions recommending bedaquiline as a first-line treatment for MDR-
TB.(9) WHO guidelines also endorse the addition of delamanid to regimens that do not 
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contain ≥5 likely effective drugs. A number of RCTs for these drugs are currently in 
progress.(10–13) Many clinical questions regarding the use of these drugs, especially in 
combination, remain unanswered at present and will not be addressed by the RCTs.  
Much of the evidence guiding treatment of MDR-TB, including the most recent WHO 
guideline revisions, has been based on observational data.(7,9,14–16) However, these 
studies have generally lacked longitudinal assessment of treatment and inadequately 
controlled for confounding, limiting their validity. With RCTs still the uncontested gold 
standard for assessing treatment efficacy, a body of research has emerged providing 
evidence that causal effects can be inferred in observational data.(17,18) The validity of 
these studies relies on scrutinizing common threats such as confounding and selection 
bias and implementing appropriate analytic methods to control for biases introduced 
when a treatment is not randomized. Applying methods, such as Robins generalized 
methods, or “g-methods,”(19) to rigorously collected longitudinal data on MDR-TB 
treatment can improve evidence that emerges from non-randomized studies of 




2 COMPARATIVE EFFECTIVENESS OF ADDING DELAMANID TO 
MULTIDRUG-RESISTANT TUBERCULOSIS REGIMENS CONTAINING 
THREE DRUGS LIKELY TO BE EFFECTIVE 
 
2.1 Introduction 
Delamanid (OPC-67683, Deltyba®) received conditional approval for use in treatment of 
TB by the European Medicines Agency in 2014.(8) It was only the second drug with a 
novel mechanism of action against M.tb to receive marketing authorization from a 
stringent regulatory authority in forty years. Results of the Phase IIb RCT showed 
delamanid to be efficacious: 45.4% of patients in the delamanid-plus-standard-treatment 
arm achieved culture conversion at 2 months vs 29.6% in the standard treatment arm 
(p=0.008).(20) However, a subsequent Phase III trial found no clinically relevant or 
statistically significant difference between arms: 87.6% in the delamanid-plus-standard-
treatment arm achieved conversion by six months vs 86.1% in the placebo-plus-standard 
treatment arm.(21) Based on the Phase III trial results, the WHO concluded in 2018 
interim guidance that “the demonstrated benefit of delamanid when added to an 
optimized background regimen was small.”(22) Delamanid was subsequently categorized 
as a lower priority Group C drug that may be included in longer MDR-TB regimens if a 
regimen cannot be composed with the more effective Group A and Group B drugs.(9) 
One observed difference between the Phase IIb and Phase III trials is composition of the 
optimized background regimen. Participants in the Phase II trial received 4-5 drugs on 
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average. The Phase III trial used an optimized background regimen comprising a mean of 
6.5 drugs. Other research has elucidated that patients treated with conventional MDR-TB 
treatment experience maximal treatment response and lowest odds of mortality when they 
receive at least 5 drugs in the initial phase.(23) This raises the possibility that the 
divergence of findings between the two trials may be because participants in the Phase III 
trial received a larger number of effective drugs, potentially masking delamanid’s 
contribution to treatment outcomes. The effect of delamanid when added to a weak 
regimen—such as in patients where a regimen is limited to only three drugs likely to be 
effective—was unknown. 
Recent WHO guidelines suggest that delamanid may have a critical role in strengthening 
regimens and have called for studies of the drug in the context of regimens compromised 
by resistance or intolerability, two features that often result in patients receiving 
suboptimal regimens with few drugs.(16) In an early report of 66 patients receiving 
delamanid under compassionate use, 80% were culture negative at 6 months.(24) Patients 
had, on average, received only 3.3 drugs likely to be effective. This treatment response—
which far exceeded that from historical cohorts treated without delamanid—suggested 
that delamanid may provide an advantage in terms of effectiveness among patients with 
limited treatment options. Subsequent descriptive studies of patients treated with 
delamanid showed similar early success, with 70-95% of patients achieving culture 
conversion within six months of delamanid initiation.(25–29) However, to date, no 
observational studies have directly compared the effectiveness of delamanid-containing 
regimens to delamanid-free regimens. 
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Here, we evaluated the effect of adding delamanid for 24 weeks to MDR-TB regimens 
comprising only three drugs likely to be effective. We estimated two-month and six-




2.2.1 Data source and study population 
We included participants with a positive baseline culture and documented RR-TB or 
MDR-TB from the endTB observational cohort (NCT02754765), a prospective research 
cohort started in 2015 to expand access to bedaquiline and delamanid in 17 countries. 
Study protocol details have been reported previously.(30) In short, participants were 
treated under routine programmatic conditions in accordance with guidelines of their 
respective countries and of WHO during the study period.(14,31) Clinical care was 
further informed by the endTB clinical guide.(32) Parent study activities were directed by 
a common protocol.(30) Data were collected using standardized forms and adverse events 
were monitored through a unified pharmacovigilance system.(33) 
2.2.2 Design of comparative effectiveness analysis 
Because the intent of the present effort was to draw inferences on the comparative 
effectiveness of adding delamanid for 24 weeks to an MDR-TB regimen of three drugs 
likely to be effective, we designed our analysis using target trial emulation.(34–38) We 
designed a hypothetical, pragmatic, RCT—a “target trial”—to answer the causal question 
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of interest. We detailed criteria of the hypothetical, pragmatic RCT, including eligibility 
criteria, treatment strategy, treatment assignment, follow-up, outcome, causal contrast, 
and statistical analysis (Appendix 5.1). We then emulated this target trial with our 
observational data and conducted a statistical analysis to control for threats to internal 
validity such as selection bias and confounding. 
2.2.3 Outcome 
Culture conversion is used as an interim microbiological indicator and surrogate endpoint 
in both observational studies and RCTs.(39,40) We assessed two- and six-month culture 
conversion risks. We defined culture conversion as the first of two consecutive negative 
cultures collected at least 15 days apart. For two-month culture conversion, the first 
culture had to be collected within the first 56 days of treatment and the second in the first 
210 days; for six-month culture conversion the first culture had to be collected within the 
first 180 days of treatment initiation and the second in the first 210 days. Participants who 
died or were LTFU before conversion were considered as not having converted. LTFU 
was defined as treatment interruption (i.e. no treatment) for ≥2 months. 
2.2.4 Definitions 
We included participants with a positive baseline sputum culture, defined as any culture 
on a sputum specimen collected up to 90 days before treatment initiation. We excluded 
patients treated in the Democratic People’s Republic of Korea due to substantial 
differences in diagnosis, treatment delivery, and lack of HIV testing, compared to the rest 
of the cohort. Likely effectiveness was defined as: (1) a drug for which resistance testing 
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indicated that the participant’s M.tb strain was not resistant to the drug, or (2) a drug for 
which no resistance testing had been conducted and the participant had not previously 
received the drug for one month or more. Baseline exposure was categorized as one of 
the following: (1) receiving a regimen of delamanid plus a background regimen of three 
drugs likely to be effective, (2) receiving a regimen of three drugs likely to be effective, 
none of which was delamanid, or (3) neither exposure group of interest. In order to allow 
for early adjustments to treatment regimens (likely unrelated to efficacy or safety), we 
categorized the baseline exposure according to the drugs prescribed on the 7th day after 
treatment initiation.  
2.2.5 Statistical analysis 
An analysis estimating the observational analogue of the intention-to-treat (ITT) effect of 
the target trial would include all participants, classify their treatment according to 
baseline, and adjust for baseline confounders. This analysis would estimate the effect of 
initiating delamanid plus a background regimen of three drugs versus a background 
regimen of three drugs, not including delamanid. However, we observed that during 
follow-up, exposure status changed: for some participants in the delamanid-containing 
group, delamanid was discontinued; for some participants in the delamanid-free group, it 
was started; and in both groups, some patients experienced changes in the number 
background drugs. Therefore, the ITT analysis could underestimate the effect of 
delamanid, if any exists. A more useful causal contrast is the observational analogue of 
the per-protocol effect, which estimates the effect of delamanid among participants 
whose baseline exposure status is maintained for the duration of the study period (24 
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weeks). Because MDR-TB treatment can vary over time, there is potential for time-
dependent confounding. Time-dependent confounding can present itself when a time-
varying variable is a risk factor for the outcome, predicts subsequent treatment, and is 
affected by past treatment.(19,41) This is likely the case in MDR-TB for factors such as 
microbiologic monitoring (e.g. sputum smear) and drug resistance monitoring.(42) We 
applied a simple technique for time-varying treatments whereby participants are 
artificially censored when their treatment deviates from that administered at baseline. To 
control for selection bias due to artificial censoring, we applied inverse probability of 
censoring weights. This technique effectively forces the time-varying treatment to be 
non-time varying, thus eliminating time-dependent confounding.(43) 
2.2.5.1 Inverse probability of censoring weights 
To simulate creation of the per-protocol population, we censored observations in the 
delamanid-containing group if delamanid had been discontinued for >2 consecutive 
weeks and there was no evidence that delamanid discontinuation was in response to an 
adverse event; if there was a documented adverse event, we did not censor. In the 
delamanid-free group, we censored observations if delamanid was added for >2 
consecutive weeks. In both groups, observations were censored if any effective 
background drug was added or removed for >2 consecutive weeks and the resulting 
regimen contained either less than three drugs likely to be effective or more than three 
drugs likely to be effective. 
Outright censoring of follow-up time after a change in exposure group will induce 
selection bias. To control for selection bias due to artificial censoring, for each individual 
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and for each week, we estimated time-varying inverse probability of censoring weights 
equal to the inverse of the probability of being uncensored, i.e. maintaining treatment 
consistent with the baseline exposure group. The use of inverse probability of censoring 
weighting creates the pseudopopulation that would have been observed if, 
counterfactually, baseline exposure was maintained in all participants (unstabilized 
censoring weights), or baseline exposure changes were at random (stabilized censoring 
weights). In the pseudopopulation, there is no confounding by baseline or time-varying 
confounders.  
To estimate the weights, we fitted a pooled logistic regression model to estimate the 
probability that each participant remained on their baseline exposure (i.e. was not 
censored) conditional on time-varying predictors of changing treatment and time since 
baseline. These predictors included time-varying number of Group A drugs, sputum 
smear result, number of adverse events, hospitalization, time, and a quadratic function of 
time (Model 2, Appendix 5.2). Some missingness occurred for time-varying sputum 
smear result, resulting in the exclusion of participants without these data. We conducted a 
sensitivity analysis comparing estimates from models with and without time-varying 
sputum smear result (Appendix 5.2 and Appendix 5.3).  
For unstabilized censoring weights (WC), we divided 1 by the probability of a participant 
remaining on their baseline exposure using the formula below where: t denotes the time 
in weeks from treatment initiation to the time-fixed culture conversion endpoint (2 
months, 6 months, death or LTFU), A is the baseline exposure (1=delamanid-containing, 
0=delamanid-free), C(t) indicates artificial censoring due to switching exposure groups at 
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time t (1= censored, 0=not censored), L"(t) represents the vector of time-varying 
covariates at time t and L represents the vector of baseline covariates used to model time-
varying covariate history. At time t, the denominator of the weight is the product of the 
predicted probability of being uncensored. 
WC (t) =  ∏ !"#	[&(()*+│-,-/((),			&((0!)*+,			1]
3
(*+ 	 
For statistical efficiency of our risk estimate, we additionally derived stabilized censoring 
weights (SWC) by fitting a second pooled logistic regression to estimate the probability of 
the participant remaining on their baseline exposure (i.e. not being censored), conditional 
on time, as represented by the following formula:  
SWC (t) = ∏ "#	(&(()*+│&((0!)*+,			1)"#	[&(()*+│-,-/((),			&((0!)*+,			1]
3
(*+  
We fitted multiple models, identifying predictors of exposure group changes a priori 
based on content knowledge. Comparisons of these models and the mean and standard 
deviation of estimated weights are described in Appendix 5.2 and 5.3.  
2.2.5.2 Estimating the per-protocol analogue relative risk and risk difference of culture 
conversion 
We identified baseline confounders of treatment using content knowledge and directed 
acyclic graphs (Appendix 5.4). We fitted multiple models to control for confounding by 
baseline characteristics, which are detailed in Appendix 5.5. We selected a final baseline 
model comprised of age, sex, whether the participant was in the hospital at treatment 
initiation, the number of Group A drugs in the regimen, whether the patient was on 
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imipenem-cilastatin, body mass index <18.5, HIV infection, and hepatitis C. Missing data 
were rare for most confounders (<1%), with the exception of baseline cavitation on chest 
radiography (Table 1, 10.7% missing). Following the principles of Greenland,(44) we 
conducted a missing indicator analysis for a composite variable representing cavitation 
and smear grade, which has been found to be highly predictive of poor treatment outcome 
(Appendix 5.6).(45,46)  
Using a weighted logistic regression model adjusted for baseline confounders of 
treatment, we estimated the predicted probabilities of culture conversion for each 
uncensored participant. We then used the mean predicted probability of conversion by 
exposure group to calculate the point estimate for the relative risk and risk difference. 
Confidence intervals were calculated using nonparametric bootstrapping with 500 
samples. Because we controlled for baseline confounders of treatment in the final logistic 
regression model (as opposed to using a composite inverse probability of treatment and 
censoring weight), estimates reflect conditional effects. 
2.2.5.3 Sensitivity analyses 
To account for the possibility that adjustment for the number of Group A drugs did not 
adequately control for the efficacy of the background regimen across exposure groups 
and given bedaquiline’s potent bactericidal activity,(47) we conducted a sensitivity 
analysis among patients who had received bedaquiline. We restricted the delamanid-
containing group to those who also received bedaquiline. All participants in the 
delamanid-free group received bedaquiline; by design, all participants in the endTB 
observational cohort either received delamanid and/or bedaquiline.  
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2.2.6 Ethical approval 
We obtained ethical approval from the central ethics review committees for each 
consortium partner and local ethical approvals in each country. Participants provided 
written informed consent.  
 
2.3 Results 
2.3.1 Analysis cohort 
Between April 1, 2015 and September 30, 2018, 2755 patients were initiated on a first 
regimen with bedaquiline and/or delamanid and consented to participate in the endTB 
observational study (Figure 2.1). We excluded 1996 (72.5%) participants whose baseline 
regimen did not fall into an exposure group of interest. Patients who did not have 
RR/MDR-TB (n=6), had a negative or missing baseline sputum culture (n=358), or were 
treated in the Democratic People’s Republic of North Korea (N=32) were excluded, 
leaving 363 participants (N=125 delamanid-containing, N=238 delamanid-free) in the 
analysis cohort (Figure 2.1).  
2.3.2 Participant characteristics 
The majority of patients were treated in Kazakhstan (30.4%), Georgia (16.8%), Peru 
(14.0%), and Pakistan (12.1%) (Table 2.1). Exposure groups were comparable with 
regard to age, sex, and indicators of disease severity such as cavitation, bilateral disease, 
and smear grade; however, missing data on cavitation and bilateral disease was more 
prevalent among participants in the delamanid-free group. The delamanid-containing 
 
13 
group consistently had a greater proportion of participants with comorbidities including 
HIV, Hepatitis B, Hepatitis C, malnutrition, and diabetes. Approximately 10% of 
participants in the delamanid-containing group had been treated exclusively with first-
line anti-TB drugs, compared to <1% of participants in the delamanid-free group (Table 
2.1).  
2.3.3 Baseline treatment regimens and regimen changes 
Although participants in both groups received a background regimen of three drugs likely 
to be effective, there was substantial heterogeneity in the drugs comprising regimens 
(Table 2.2). On average, participants in the delamanid-containing group had fewer Group 
A drugs, those classified as priority drugs in the 2020 WHO MDR-TB treatment 
guidelines.(5) While 69.8% (n=166/238) of the delamanid-free group participants 
received all three Group A drugs (bedaquiline, linezolid, levofloxacin/moxifloxacin) or 
two Group A drugs (bedaquiline, linezolid) and one Group B drug (clofazimine), only 
39.2% (n=49/125) of the delamanid-containing group participants received the 
combination containing bedaquiline, linezolid, and clofazimine and none received all 3 
Group A drugs (Table 2.2). 
Baseline exposure group was maintained for 24 continuous weeks (Figure 2.2) in 
approximately 60% of participants. Of the 132 whose exposure group changed, 34 had 
short term (<2 week) changes; in one participant, delamanid was removed due to an 
adverse event. These participants were not censored. The remaining 97 participants had 
regimen adjustments that resulted in an exposure group change and censoring: in 8, 
delamanid was added; in 4 delamanid was withdrawn without a documented, related 
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adverse event; and 85 had a background regimen change resulting in a change to the 
participant’s exposure group (Figure 2.2). Unstabilized censoring weights had a mean of 
1.35 (SD 0.44); stabilized censoring weights were a mean of 0.98 (SD 0.32) (Appendix 
5.2). Adjusted estimates were calculated based on the sample of 349 participants with 
complete data (Table 2.3). Twelve participants were excluded from the analysis due to 
missing data on time-varying sputum smear used to calculate censoring weights. The 
exclusion of this variable and subsequent inclusion of these participants in a sensitivity 
analysis resulted in only a minor change to the point estimate (Model 4 vs Model 2, 
Appendix 5.3). 
2.3.4 Two-month sputum culture conversion 
At two months, 49.6% of participants in the delamanid-containing group and 55.9% of 
participants in the delamanid-free group experienced culture conversion. Among 
participants who did not have culture conversion, 6 (4.8%) (3 deaths, 3 LTFU) 
participants in the delamanid-containing group and 7 (2.9%) (2 deaths, 5 LTFU) 
participants in the delamanid-free group died or were LTFU in the first two months (data 
not shown). The adjusted analysis using stabilized weights resulted in a risk ratio of 0.93 
(95% CI: 0.70, 1.33) and a risk difference of -0.04 (95% CI: -0.18, 0.16) (Table 2.3) for 
delamanid-containing versus delamanid-free regimens. 
2.3.5 Six-month sputum culture conversion 
By six months, 80.8% of participants in the delamanid-containing and 89.1% of 
participants in the delamanid-free group experienced sputum culture conversion. Fifteen 
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(12.0%) (7 deaths, 8 LTFU) participants in the delamanid-containing group died or were 
LTFU before conversion versus 14 (5.9%) (4 deaths, 10 LTFU) in the delamanid-free 
group (data not shown). Using stabilized weights, the adjusted risk ratio of six-month 
sputum culture conversion was 0.93 (95% CI: 0.78, 1.05) and risk difference was -0.06 
(95% CI: -0.89, 0.05) (Table 2.3) for delamanid-containing versus delamanid-free 
regimens. 
2.3.6 Sensitivity analyses 
When we restricted analyses to participants receiving bedaquiline in their baseline 
regimen, the two-month risk ratio of culture conversion was 0.97 (95% CI: 0.66, 1.42) 
and risk difference was -0.02 (95% CI: -0.20, 0.20) (Table 2.3). Estimates for six-month 
culture conversion shifted rightward towards the null, with a risk ratio of 1.02 (95% CI: 
0.94, 1.11) and risk difference of 0.02 (95% CI: -0.06, 0.10) (Table 2.3).  
 
2.4 Discussion 
We identified a null effect of adding delamanid to a regimen containing only three other 
drugs likely to be effective. In this context, delamanid added little, consistent with the 
previously reported Phase III delamanid trial but different from those of the Phase IIb 
trial.(20,21) 
Adding delamanid to a regimen with only three drugs did not improve culture conversion 
in our study.(5) Our treatment groups were defined by the quantity of drugs in a regimen. 
However, the efficacy of drugs in the regimen cannot be ignored. The advent of 
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bedaquiline, repurposed drugs, such as linezolid and clofazimine, and late generation 
quinolones, such as levofloxacin/moxifloxacin, have innovated the TB drug and regimen 
landscape. Regimens of lesser efficacy, like those used in the Phase IIb trial that showed 
a significant effect of delamanid,(20) are not represented in large numbers in the endTB 
cohort. The majority of participants in the endTB cohort received linezolid (82%), 
clofazimine (73%), bedaquiline (73%), or levofloxacin/moxifloxacin (58%) at 
baseline.(46) These regimens more accurately reflect the efficacy of those used in the 
Phase III trial,(21) which also identified no effect of adding delamanid to a regimen. 
Thus, it is not surprising our findings are similar. Whether delamanid can improve the 
effectiveness of regimens compromised by toxicity or resistance to the aforementioned 
new and repurposed drugs remains unanswered. The regimens needed to answer this 
research question would have efficacy that aligns more closely with the efficacy of the 
background regimen employed in the Phase IIb trial. 
There was more death and LTFU in the delamanid-containing group (12.0%) than in the 
DLM-free group (5.9%). This may be because participants in the delamanid-containing 
group had more comorbid conditions highly predictive of early death and poor treatment 
outcome, such as HIV, and more fluoroquinolone and injectable resistance.(46,48) Our 
outcome definition considered death and LTFU occurring before conversion as non-
conversion events, which is in accordance with how these events are classified as 
unsuccessful final treatment outcomes according to WHO criteria. An alternative 
approach would be to create a second set of censoring weights for death and LTFU, 
exclude participants with these events, and weight the remaining participants accordingly 
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to adjust for selection bias from artificially censoring participants who died or were 
LTFU.(49) The estimate from such an analysis would represent the effect of adding 
delamanid to the regimen, assuming there were no deaths or LTFU in the study.  
Our analysis assessed culture conversion at two and six months. While culture conversion 
is a commonly used surrogate endpoint or prognostic marker for treatment outcome in 
RCTs, conversion does not perfectly predict clinical benefit. In fact, the extent to which 
sputum-based endpoints at various timepoints can predict treatment outcomes (e.g. 
favorable vs unfavorable, relapse free cure) is a point of debate. Reanalysis of trials in 
drug-sensitive TB and MDR-TB have provided contradictory evidence in which some 
studies have concluded sputum-based markers can predict outcomes,(40,50–52) while 
other studies provide evidence questioning the statistical validity of sputum-based 
markers.(53–55) Observational studies have also yielded contradictory findings across 
studies.(39,56,57) Despite the absence of conclusive evidence on the role of conversion 
in predicting treatment outcome, culture conversion remains a commonly used early 
outcome in MDR-TB treatment. Future analyses of the discriminatory power of two and 
six month conversion are needed within the context of the endTB cohort to fully 
understand how our study’s findings extend to final treatment outcome.  
Our study has several limitations. First, despite narrowly defining our exposure groups, 
there may be residual differences in the quality of the background regimen across 
exposure groups. We attempted to control for the efficacy of regimens across exposure 
groups by adjusting for the number of Group A drugs. Few efforts have been made to 
meaningfully capture the heterogeneity of MDR-TB regimens in comparative 
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effectiveness studies, likely because hundreds or even thousands of distinct regimens can 
be represented in any one cohort. For example, the 2012 individual patient data meta-
analysis comprises over 9000 patients on 1626 different regimens.(58,59) Further 
methodologic work in this area is needed, as global treatment guidance relies largely on 
observational cohorts for the evidence base.(23,58) Second, there are a number of 
assumptions that must be met in observational studies in order for our estimates to be 
valid. The assumption that often garners the most focus is that all confounders must be 
adjusted for. We cannot rule out the possibility of residual confounding, though we built 
multiple baseline models to adjust for measured confounders of treatment and 
conversion. The probability there were additional unmeasured confounders is likely low, 
given that we collected a multitude of data on baseline factors. All prognostic factors 
predicting exposure group changes must also have been identified and accurately 
modeled to rule out unmeasured confounding and residual confounding. Correct model 
specification cannot be guaranteed, however we built multiple censoring weight models 
and the results did not meaningfully change. A major strength of our study and the reason 
we were able to conduct a censoring weighted analysis is that we collected an abundance 
of time-varying risk factors that have historically not been represented in previous 
cohorts. Without these data, such an analysis would not have been possible. 
In sum, we did not identify an effectiveness benefit of adding delamanid to an MDR-TB 
regimen with a suboptimal number of drugs. However, critical questions related to 
delamanid’s role in MDR-TB regimens remain, including whether delamanid can 
improve the effectiveness of regimens comprised of drugs with suboptimal efficacy.  
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2.5 Tables and Figures 
Table 2.1 Baseline characteristics of participants receiving three drugs likely to be 









n (%) N (%) n (%) 
Demographic       
Site 
11 (8.8) 10 (4.2) 21 (5.8) Armenia      
Bangladesh   9 (7.2) 25 (10.5) 34 (9.4) 
Belarus      15 (12.0) 2 (0.8) 17 (4.7) 
Georgia      12 (9.6) 49 (20.6) 61 (16.8) 
Haiti        5 (4.0) 0 0 5 (1.4) 
Indonesia    0 0 1 (0.4) 1 (0.3) 
Kazakhstan   54 (43.2) 56 (23.5) 110 (30.3) 
Kyrgyzstan   2 (1.6) 2 (0.8) 4 (1.1) 
Lesotho      4 (3.2) 5 (2.1) 9 (2.5) 
Myanmar      3 (2.4) 0 0 3 (0.8) 
Pakistan     9 (7.2) 35 (14.7) 44 (12.1) 
Peru         0 0 51 (21.4) 51 (14.0) 
South Africa 1 (0.8) 0 0 1 (0.3) 
Vietnam      0 0 2 (0.8) 2 (0.6) 
Age, median (SD) 39 (11.6) 35 (12.6) 36 (12.3) 
Gender 
80 (64.0) 166 (69.7) 246 (67.8) Male 
Disease severity       
Baseline cavity 
6 (4.8) 33 (13.9) 39 (10.7) Missing 
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Cavitation 90 (72.0) 140 (58.8) 230 (63.4) 
No cavitation               29 (23.2) 65 (27.3) 94 (25.9) 
Bilateral disease 
3 (2.4) 26 (10.9) 29 (8.0) Missing 
Bilateral     89 (71.2) 145 (60.9) 234 (64.5) 
Non-bilateral 33 (26.4) 67 (28.2) 100 (27.5) 
Smear grade (-90 days, +0 days from treatment initiation) 
Missing 1 (0.8) 4 (1.7) 5 (1.4) 
Scanty 1-3 3 (2.4) 2 (0.8) 5 (1.4) 
Scanty 4-9 4 (3.2) 8 (3.4) 12 (3.3) 
One plus 44 (35.2) 76 (31.9) 120 (33.1) 
Two plus 23 (18.4) 44 (18.5) 67 (18.5) 
Three plus 15 (12.0) 37 (15.5) 52 (14.3) 
Disease site 
0 0 3 (1.3) 3 (0.8) Extrapulmonary 
Pulmonary      125 (100.0) 235 (98.7) 360 (99.2) 
Comorbidities       
HIV 
1 (0.8) 0 0 1 (0.3) Missing 
Negative 106 (84.8) 227 (95.4) 333 (91.7) 
Positive 18 (14.4) 11 (4.6) 29 (8.0) 
Hepatitis B 
1 (0.8) 0 0 1 (0.3) Missing 
Negative 116 (92.8) 231 (97.1) 347 (95.6) 
Positive 8 (6.4) 7 (2.9) 15 (4.1) 
Hepatitis C  
2 (1.6) 0 0 2 (0.6) Missing 
Negative 96 (76.8) 212 (89.1) 308 (84.8) 
Positive 27 (21.6) 26 (10.9) 53 (14.6) 
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Malnutrition (body mass index <18.5) 
2 (1.6) 0 0 2 (0.6) Missing 
No malnutrition 71 (56.8) 155 (65.1) 226 (62.3) 
Malnutrition 52 (41.6) 83 (34.9) 135 (37.2) 
Anemia 
4 (3.2) 2 (0.8) 6 (1.7) Missing 
No anemia 70 (56.0) 120 (50.4) 190 (52.3) 
Anemia    51 (40.8) 116 (48.7) 167 (46.0) 
Diabetes 
1 (0.8) 3 (1.3) 4 (1.1) Missing 
No diabetes 97 (77.6) 208 (87.4) 305 (84.0) 
Diabetes 27 (21.6) 27 (11.3) 54 (14.9) 
Indications       
Previous TB treatment       
Missing 7 (5.6) 4 (1.7) 11 (3.0) 
Only with first-line drugs 13 (10.4) 2 (0.8) 15 (4.1) 
With second-line drugs 105 (84.0) 232 (97.5) 337 (92.8) 
Indication for DLM and BDQ       
Construction of regimen of 4 likely 
effective second-line drugs not 
possible 115 (92.0) 238 (100.0) 353 (97.2) 
Other high risk of unfavorable 
outcome                                    10 (8.0) 0 0 10 (2.8) 
Existing neuropathy       
Missing 38 (30.4) 57 (23.9) 95 (26.2) 
Existing neuropathy 20 (16.0) 36 (15.1) 56 (15.4) 
None                     67 (53.6) 145 (60.9) 212 (58.4) 
Hearing loss at baseline (2 contiguous Hz each >= 30dB in either ear) 
Missing 52 (41.6) 81 (34.0) 133 (36.6) 
At least some hearing loss 44 (35.2) 85 (35.7) 129 (35.5) 
No hearing loss            29 (23.2) 72 (30.3) 101 (27.8) 
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Prolonged QTcF interval       
Missing 34 (27.2) 83 (34.9) 117 (32.2) 
Normal QTcF  90 (72.0) 148 (62.2) 238 (65.6) 
Prolonged QTcF (>450 ms) 1 (0.8) 7 (2.9) 8 (2.2) 
Abbreviations: standard deviation (SD), delamanid (DLM), bedaquiline (BDQ), hertz 




Figure 2.1 Flowchart of patients eligible for the comparative effectiveness of 
delamanid analysis in the endTB observational cohort 
  
Patients enrolled in the endTB observational 
study April 1, 2015-September 30, 2018  
N=2755 
Not RR-TB or MDR-TB 
N=6 
Regimen received on 7th day 
of treatment was consistent 
with neither intervention nor 
comparator definition 
N=1996 
Baseline culture negative or 
missing 
N=358 
Patients receiving a regimen of delamanid 
plus 3 likely effective drugs (intervention) or 
3 likely effective drugs (not delamanid) 
(comparator)  
N=759 
Patients included in the analysis 
N=363 
Patients treated in the 





Table 2.2 Baseline treatment regimens of participants receiving three drugs likely to 






n (%) n (%) 
3 Group A drugsb         
Lfx/Mfx, Bdq, Lzd  - 24 (10.1) 
2 Group A drugsb         
Bdq, Lzd, Cfz 49 (39.2) 142 (59.7) 
Lfx/Mfx, Lzd, Cfz 12 (9.6)  - 
Bdq, Lzd, ImCil/M 1 (0.8) 20 (8.4) 
Bdq, Lzd, Csn/Trd 1 (0.8) 16 (6.7) 
Lfx/Mfx, Bdq, Cfz 1 (0.8) 4 (1.7) 
Bdq, Lzd, Km/Cm  - 4 (1.7) 
Bdq, Lzd, PASms/PAS  - 4 (1.7) 
Lfx/Mfx, Lzd, ImCil/M 2 (1.6)  - 
Lfx/Mfx, Lzd, Csn/Trd 2 (1.6)  - 
Lfx/Mfx, Lzd, Eto/Pto 2 (1.6)  - 
Lfx/Mfx, Bdq, Csn/Trd  - 3 (1.3) 
Bdq, Lzd, Eto/Pto 1 (0.8) 1 (0.4) 
Lfx/Mfx, Bdq, Km/Cm 1 (0.8)  - 
Lfx/Mfx, Lzd, Km/Cm 1 (0.8)  - 
Bdq, Lzd, E  - 1 (0.4) 
Lfx/Mfx, Bdq, E  - 1 (0.4) 
Lfx/Mfx, Bdq, PASms/PAS  - 1 (0.4) 
1 Group A drugb         
Lzd, Cfz, ImCil/M 26 (20.8)  - 
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Lfx/Mfx, Csn/Trd, Eto/Pto 7 (5.6)  - 
Bdq, Cfz, ImCil/M 3 (2.4) 5 (2.1) 
Bdq, Cfz, Km/Cm  - 5 (2.1) 
Lzd, Cfz, Km/Cm 2 (1.6)  - 
Lzd, Cfz, PASms/PAS 2 (1.6)  - 
Lzd, Cfz, S/A 2 (1.6)  - 
Lfx/Mfx, Cfz, Eto/Pto  - 2 (0.8) 
Bdq, Cfz, S/A 1 (0.8)  - 
Bdq, Csn/Trd, PASms/PAS 1 (0.8)  - 
Lfx/Mfx, Cfz, ImCil/M 1 (0.8)  - 
Lfx/Mfx, Eto/Pto, PASms/PAS 1 (0.8)  - 
Lzd, Cfz, E 1 (0.8)  - 
Lzd, Cfz, Z 1 (0.8)  - 
Lzd, ImCil/M, Km/Cm 1 (0.8)  - 
Lzd, Csn/Trd, PASms/PAS 1 (0.8)  - 
Bdq, Cfz, Eto/Pto  - 1 (0.4) 
Bdq, Cfz, PASms/PAS  - 1 (0.4) 
Bdq, ImCil/M, Eto/Pto  - 1 (0.4) 
Bdq, Csn/Trd, Eto/Pto  - 1 (0.4) 
H, Bdq, ImCil/M  - 1 (0.4) 
No Group A drugsb 1 (0.8)  - 
Cfz, Csn/Trd, Eto/Pto 1 (0.8)  - 
Abbreviations: bedaquiline (Bdq), clofazimine (Cfz), cycloserine or terizidone (Csn/Tzd), 
ethambutol (E), ethionamide or prothionamide (Eto/Pto), imipenem-cilastatin-amoxicillin 
clavulanate or meropenem (ImCil/M), levofloxacin or moxifloxacin (Lfx/Mfx), linezolid (Lzd), 
p-aminosalicylic acid (PAS), pyrazinamide (Z), streptomycin or amikacin (S/A) 
a All participants on a delamanid-containing regimen also received delamanid (not shown in 
regimen list) 




Figure 2.2 Flowchart of participants censored due to changing treatment strategies 
in the endTB observational cohort 
 
  
Participants eligible for the delamanid 
analysis 
N=363 
Treatment strategy change <2 
weeks duration 
N=34 
Maintained baseline treatment 
strategy classification until end 
of follow up 
N=231 
Allowable delamanid removal 
due to adverse event  
N=1 




- Added delamanid (n=8) 
- Removed delamanid without documentation of adverse event (n=4) 






Table 2.3 Effect of adding delamanid to a regimen composed of three drugs likely to be effective, endTB observational 
cohort (N=363) 
  Two-month culture conversion Six-month culture conversion 
Analysis N RR (95% CI) RD (95% CI) RR (95% CI) RD (95% CI) 
Crude 363 0.89 (0.72, 1.09)  -0.06 (-0.17, 0.05) 0.91 (0.82, 1.00) -0.08 (-0.16, -0.00) 
IP censoring weighted, unstabilized 349a 0.94 (0.67, 1.41) -0.04 (-0.20, 0.20) 0.93 (0.78, 1.05) -0.06 (-0.21, 0.05) 
IP censoring weighted, stabilized 349a 0.94 (0.71, 1.31) -0.04 (-0.18, 0.16) 0.93 (0.80, 1.05)  -0.06 (-0.19, 0.05) 
IP censoring weighted, stabilized, 
among patients on BDQ 288
b 0.97 (0.66, 1.42) -0.02 (-0.20, 0.20) 1.02 (0.94, 1.11) 0.02 (-0.06, 0.10) 
Abbreviations: Inverse probability (IP), risk ratio (RR), risk difference (RD), bedaquiline (BDQ) 
a N=10 participants excluded for missing time-varying data, N=2 participants excluded for missing baseline and time-varying data, 
N=2 participants excluded for missing baseline data 




3 SELECTION BIAS IN MULTIDRUG-RESISTANT TUBERCULOSIS 




During treatment of TB, particularly DR-TB, sputum samples are routinely collected and 
inoculated in culture medium and monitored for growth of M.tb. Conversion of sputum 
culture from positive to negative for M.tb is the most important indicator of treatment 
response.(9,60) Sputum culture conversion is also often used as a proxy for final 
treatment outcome (e.g. cure, treatment failure, or relapse) in RCTs and observational 
cohort studies alike.(39,40) While RCTs use standard protocols with sampling at 
established, frequent intervals, observational cohorts of TB patients are followed under 
routine conditions. Although the WHO recommends monthly culture monitoring,(61) in 
this context, patient encounters and sample collection may occur less frequently, and 
limited laboratory services or reagent stock-outs can result in sparse or inconsistent 
culture data.   
An initial positive sputum culture is a pre-requisite to observe conversion to negative 
sputum culture. Only patients with positive sputum cultures at a pre-defined “baseline” 
timepoint (generally expected to be before treatment initiation) are included in such 
analyses; that is, patients with a negative baseline culture or a missing baseline culture 
result are excluded. Under routine conditions, patients might not have a documented 
positive culture immediately before treatment initiation. Therefore, investigators may 
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define an interval before the day of treatment initiation that constitutes a baseline culture. 
In some cases, investigators may even extend this interval past treatment initiation in 
order to include patients who lacked a positive pre-treatment culture but had a positive 
culture after treatment initiation. While this latter approach can improve precision by 
increasing sample size, a post-treatment initiation extension could also introduce 
selection bias. This is because patients added to the analysis cohort will include those 
without a positive pre-treatment culture who survived or were retained long enough to 
have a recorded positive baseline culture in the allowable post-treatment interval, but 
exclude those with a missing pre-treatment culture who die or are LTFU during this 
interval, events that are often defined as non-conversions. Here, we refer to this bias 
mechanism as selection bias. Inclusion in the study requires a subset of patients (i.e. 
patients missing a pre-treatment culture) to survive or be retained in the study long 
enough to make it past a selection process (i.e. having a culture in the post-treatment 
initiation interval).(62) The ramifications of selection bias have been assessed at length in 
the epidemiologic literature, both in concept and applied in data from substantive areas 
such as perinatal epidemiology,(63–66) trauma,(67) cancer,(68) and HIV.(69)  
Using simulations and observational data from a cohort of patients treated for DR-TB, we 
investigate the potential for bias in reporting the absolute proportion of a cohort with 






3.2.1 Absolute proportion of patients with sputum-culture conversion 
3.2.1.1 Quantifying bias using simulated data 
To investigate selection bias due to extending the baseline culture definition interval past 
treatment initiation, we first simulated a hypothetical cohort without missing data and 
then introduced missingness. Conducting bias analyses in real-world data is limited by 
the range of values observed in the dataset. By simulating data, we can generate the full 
range of potential values for each parameter (e.g. the proportion of patients culture 
positive, the proportion of patients with a missing pre-treatment culture) and better 
understand how parameters interact.(70,71) The outcome of interest was culture 
conversion, defined as two, consecutive negative cultures at least 15 days apart. Death or 
LTFU before conversion were treated as non-conversion events. To simulate a 
hypothetical cohort, we specified the parameters below using the values listed in Table 
3.1:  
- Culture positivetruth (Pt), represents the proportion of patients who would have 
been observed to be culture positive at the time of treatment initiation, had they 
had a sputum culture result. The proportion of culture negative patients is 
therefore calculated by 1-Pt. 




- Culture positivetruth│Culture missingobserved (Pt│m), represents the proportion of 
patients with a missing pre-treatment culture, who would have been observed to 
have a positive culture at treatment initiation, had they had a culture 
- Converted│Culture positivetruth (C│Pt), represents the proportion of patients with 
conversion among patients who would have been observed to have a positive 
culture at the time of treatment initiation, had they had a sputum culture result 
The proportion with culture conversion is calculated by dividing the number of patients 
observed to have converted by the number of patients observed with a positive baseline 
culture. We calculate the observed proportion with culture conversion 




. This formula effectively includes all conversion events in the 
numerator and subtracts from the denominator patients missing a culture who would have 
been positive, had they had a culture. We hypothesized that early deaths and LTFUs 
occurring during the post-treatment allowable interval would drive the differences 
between true and observed conversion frequencies, and therefore that conversion in 
patients missing a pre-treatment culture occurred at an equal or lower frequently than 
among patients observed to have a pre-treatment culture. This assumption effectively 
limits C│PO to values greater than or equal to C│Pt. 
We report the difference between C│Pt and C│PO and the minimum and maximum 
proportion of the cohort observed to have converted and percentage point discrepancy 
between the two figures. We excluded combinations of values producing results that 
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exceeded the 0.00 to 1.00 bounds of a proportion. 
3.2.1.2 Quantifying maximum bias in the endTB observational cohort 
In order to determine the extent to which bias might have impacted a real cohort of DR-
TB patients, we used data from the endTB observational cohort (ClinicalTrials.gov 
record NCT02754765). The endTB observational cohort is a prospective cohort of 
patients with DR-TB treated with bedaquiline and/or delamanid. Patients were eligible 
for inclusion if they initiated an endTB treatment regimen between 04/01/2015 and 
11/16/2018. Data collection followed a standardized common protocol, which has been 
previously described.(30) 
We compared a baseline culture definition with an allowable interval of 90 days before (-
90) and 0 days after (+0) treatment initiation to definitions that extended the allowable 
interval to 30, 60 and 90 days past treatment initiation (-90/+30 days, -90/+60 days, -
90/+90 days). For the latter definitions, patients who had any positive culture(s) during 
the specified interval were considered to have a positive baseline culture; those who had 
consistently negative culture(s) during the specified interval were considered to have a 
negative baseline culture. Patients without any cultures during the specified interval were 
classified as having a missing baseline culture.  
We used an interim endpoint of six-month culture conversion. While definitions of six-
month culture conversion are not standardized and vary considerably in the literature,(72) 
our definition requires two consecutive negative cultures collected at least 15 days apart, 
the first occurring up to 180 days after treatment initiation and the second up to 210 days 
after treatment initiation. For baseline culture definitions extending past treatment 
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initiation (-90/+30, -90/+60, -90/+90), negative cultures fulfilled the culture conversion 
definition only if they were performed on sputum samples that were collected after the 
first positive culture had been established. Participants who died or were lost to follow-up 
before sputum culture conversion were considered not to have converted because these 
events are considered unfavorable final TB treatment outcomes.(73) Death was defined 
as death due to any cause and LTFU was defined as treatment interruption for two or 
more consecutive months.  
For each of the four baseline culture intervals, we quantified the observed proportion of 




When the interval is extended past treatment initiation, we report the additional number 
of participants added to the analysis and the number of participants missing a baseline 
culture who died or were LTFU during the interval. In order to investigate the upper 
bound of the magnitude of bias, we calculated the proportion converted “assuming 




This equation reflects maximum bias in that it presumes that 100% of patients with a 
missing pre-treatment culture who died or were LTFU during the post-treatment initiation 
culture interval would have been observed to be culture-positive, had they received a 




3.2.2 Relative proportion of patients with sputum-culture conversion 
Using data from the endTB observational cohort, we assessed the impact of extending the 
baseline culture interval past treatment initiation on the crude relative risk of common 
six-month culture conversion predictors. Risks were calculated with the same formulas as 
C│PO and C│Pmb. To assess bias we consider log risk ratios from models using 
definitions extending the baseline culture interval past treatment initiation (i.e. -90/+30, -
90/+60, -90/+90 days) to be represented by β-90/+≥1. The log risk ratio using a definition 
that does not extend the baseline culture interval past treatment initiation (i.e.-90/+0) is 
represented by β-90/+0. The percentage of bias in β-90/+≥1 due to extending the culture 
collection interval past treatment initiation is thus represented by 
?@A(B)*+/-./)	&	?@A(B)*+/-+)	
?@A(B)*+/-+)
× 100. To assess precision, we calculate the mean squared 
error for each estimate as follows: (β-90/+≥1 - β-90/+0)2 + (SE(β-90/+≥1)2. 
We considered the following dichotomous predictors: diabetes mellitus or glucose 
intolerance, poorly controlled diabetes (HbA1c >8.0%), HIV infection, CD4 cell count 
<200 cells/mL, Hepatitis B virus infection, Hepatitis C virus infection, prior TB treatment 
with second-line drugs, bilateral disease, cavitary disease, and BMI <18.5.  
 
3.3 Results 
3.3.1 Absolute proportion of patients with sputum-culture conversion 
3.3.1.1 Quantifying bias using simulated data 
Combinations of the values listed in Table 3.1 resulted in 420 potential scenarios; 66 
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exceeded the 0.00 to 1.00 bounds for a proportion and were excluded from the analysis, 
leaving 354 results.  Figure 3.1 provides a guided interpretation of simulation study 
results presented in Figures 3.2-3.4 and annotates two of the most influential drivers of 
bias. In brief, the colored horizontal line represents the true proportion of the cohort with 
culture conversion (C│Pt). The shaded region indicates the potential minimum and 
maximum bias as a function of the proportion of patients who died or were LTFU among 
those missing a pre-treatment at the value of m on the x-axis.  Thus, the upper bound of 
the shaded region (indicated by ■ in Figure 3.1) represents the proportion observed if all 
patients missing a pre-treatment culture had died or been LTFU (i.e. did not convert). The 
lower bound of the shaded region (indicated by ● in Figure 3.1) reflects the point at 
which conversion rates in patients missing a pre-treatment culture and patients observed 
to have a pre-treatment culture were the same. This value is equal to  C│Pt ‐ 1. The two 
most influential drivers of bias, as shown by the width of the shaded region, are the 
proportion of patients missing a pre-treatment culture (x-axis) and the proportion of these 
patients who died or were LTFU (vertical point within shaded region). 
Four key patterns emerged from the simulation. First, the potential for bias increases as 
the proportion missing a pre-treatment culture (m) increases, as shown by the larger 
width of shaded regions at higher values of the x-axis in Figures 3.2-3.4. Second, the 
potential for bias is limited in cohorts with high rates of conversion, as shown by the 
leveling off of the shaded region’s upper bound at 100% where C│Pt=90% and m=~15% 
in Figure 3.2. This is because the upper bound of the shaded region reflects a scenario in 
which all patients missing a pre-treatment culture die or are LTFU, both of which are 
 
36 
considered non-conversion events, during the allowable interval. Third, holding other 
parameters fixed, as the proportion of patients in a cohort who are truly culture positive at 
treatment initiation (Pt) increases from 60% to 90%, the potential magnitude of maximum 
bias decreases, as shown by the decreasing shaded regions’ widths across the panel in 
Figure 3.3. This is because the exclusion of the same number of patients from a cohort 
with a smaller denominator (e.g. 60% of cohort is culture positive) is more influential on 
the observed proportion with culture conversion than in a cohort with a larger 
denominator (e.g. 90% of cohort is culture positive). Lastly, the magnitude of maximum 
bias is dependent on the proportion of patients who are truly culture positive among those 
missing a pre-treatment culture (Pt│m) (Figure 3.4). If all patients missing a pre-
treatment culture are truly culture negative, these patients would have been excluded 
from analyses of culture-based endpoints and no bias will be introduced. Conversely, if 
all patients missing a pre-treatment culture are truly culture positive, these patients should 
be included and the magnitude of bias will depend on the amount of missingness, early 
death and LTFU rates in this subset of the cohort, and to a lesser extent, the proportion of 
patients truly culture positive at treatment initiation. 
3.3.1.2 Quantifying maximum bias in the endTB observational cohort data 
Between April 6, 2015 and November 16, 2018, 2790 participants initiated a regimen and 
consented to participation in the endTB observational study. Of these, 1769 participants 
had a positive pre-treatment culture within 90 days before treatment initiation (-90/+0) 
(Table 3.2) and a six-month culture conversion outcome (Table 3.3). Assuming a baseline 
culture definition that does not extend past treatment initiation (-90/+0), 86% 
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(N=1518/1769) of the cohort achieved culture conversion by 6 months. The observed 
proportion with culture conversion did not change from 86% when the baseline culture 
definition was extended to 30, 60, or 90 days past treatment initiation. 
Seventeen participants without a culture died or were LTFU in the 30-day period after 
treatment initiation, the majority of which were in Lesotho, a high HIV burden country. 
Assuming these participants would have been culture positive if they had had a culture 
(i.e. maximum bias), the proportion with culture conversion would be one percentage 
point lower (85%, N=1614/1900) than the observed proportion with culture conversion 
(Table 3.3 and Figure 3.5 -90/+30 days). The potential magnitude of maximum bias 
differed by site. Deaths or LTFU events in the first 30 days of treatment occurred among 
participants missing a pre-treatment culture in 6/17 (35%) sites (Table 3.3). We report a 
one to five percentage point discrepancy between the observed proportion with culture 
conversion and proportion with culture conversion assuming maximum bias (Figure 3.5, -
90/+30 days) in these 6 sites. 
In the 60- and 90-day periods after treatment initiation, death and LTFU events among 
participants missing a culture increased to 24 and 26, respectively (Table 3.3). Among all 
participants, the proportion with culture conversion assuming maximum bias was two 
percentage points lower (84%) than the observed, based on a definition that extended the 
baseline culture definition 60 or 90 days after treatment initiation. A death or LTFU event 
among participants missing a culture occurred in 8/17 (47%) sites (Table 3.3), resulting 
in a reported proportion with culture conversion of up to a 5 percentage point 
overestimate (Figure 3.5, -90/+60 and -90/+90 days). One site (Kenya) had a 10 
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percentage point discrepancy using a -90/+90 definition (Figure 3.5, -90/+90 days); 
however, this site had an extremely small sample size (N=4). 
3.3.2 Relative proportion of patients with sputum-culture conversion 
3.3.2.1 endTB observational cohort data 
We show the crude log relative risk of predictors on sputum culture conversion in the 
endTB observational cohort when extending the baseline culture definition 30 (Figure 
3.6), 60 (Figure 3.7) and 90 days (Figure 3.8) after treatment initiation. Using a definition 
that does not extend the sputum collection interval past treatment initiation as a reference, 
the largest discrepancies were observed for HIV infection and CD4 cell count <200 
cells/mL. Extending the sputum collection interval by 30 days past treatment initiation 
resulted in a 2.3% change in the relative risk for HIV (0.83 at -90/+0 days vs 0.85 at -
90/+30 days); assuming maximum bias drew the point estimate back towards the 
reference estimate (Table 3.4). Similar results were observed in the -90/+60 (Table 3.5) 
and -90/+90 days (Table 3.6) analyses. When accounting for death and LTFU after 
treatment initiation, bias in CD4 cell count <200 cells/mL point estimates exceeded 5% in 
the -90/+60 (Table 3.5) and -90/+90 days (Table 3.6) analyses. MSE differences across 
estimates were negligible.  
 
3.4 Discussion 
Using simulated data and in a real-world cohort study, we investigated the potential for 
selection bias when extending baseline culture definitions to include a period after 
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treatment initiation. Our findings have important implications for investigators reporting 
on basic epidemiologic parameters of DR-TB treatment cohorts, including the proportion 
with culture conversion and the relative risk of common predictors of culture conversion. 
In the present analyses, we identified the most influential factors that increased bias were 
the proportion of the cohort with a missing pre-treatment culture and the occurrence of 
death and LTFU in this group.   
Simulation studies are a valuable tool for exploring complex theoretical biases in 
epidemiology, which can be especially useful in contexts where a “true” dataset will 
never be realized, such as in the case of selection bias. However, simulations are only 
useful insofar they are encoded with values that can play out in real life.(70) In our 
simulation, we present the entire spectrum of potential bias in the reported proportion 
with culture conversion. In reality, conversion overestimates are likely much less than the 
maximum presented in simulations, as shown by the upper bound of the shaded region, 
because it is improbable everyone missing a pre-treatment culture dies or is LTFU in the 
post-treatment initiation interval. These smaller estimated changes would suggest that a 
missing pre-treatment culture is not necessarily due to early death or LTFU. A large 
overestimate (e.g. 20-30 percentage points) could occur if a large percentage (20–30%) of 
culture-positive patients were missing a pre-treatment culture and the majority of these 
patients died or were LTFU in the post-treatment initiation interval. However, high rates 
of early death are uncommon in today’s cohorts given advances in treatment that have 
drastically reduced mortality.(74,75) However, the same cannot be said for historical 
cohorts. High early death rates were common among patients with advanced drug-
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resistance and HIV co-infection, such as in South Africa.(76) In fact, among patients 
initiating DR-TB treatment in South Africa between 2012 and 2014, 10% of the cohort 
died within the first 12 weeks of treatment and a missing or contaminated baseline culture 
was the strongest predictor of mortality (hazard ratio: 3.78, 95% CI: 2.90-3.99).(77) 
While this study did not assess culture conversion, it does serve as an example of a cohort 
for which extending the allowable baseline interval past treatment initiation could 
introduce bias.  
We identified notable heterogeneity across sites in analyses assessing maximum bias of 
the proportion with culture conversion in the endTB cohort. These site-specific 
differences provide some insight into how this mechanism of selection bias can play out 
across settings with vastly different prevalence of comorbidities. For example, high rates 
of early death and LTFU occurred in Lesotho, potentially due to a higher prevalence of 
HIV and advanced drug resistance. And, in Kenya, even one or two early death or LTFU 
events drastically biased the proportion with conversion due to the site’s small sample 
size. Many reports of MDR-TB clinical cohorts are confined to small groups of patients 
treated in the same geographic settings with similar comorbidities. Results from the 
simulation also reinforce that low rates of conversion and low proportions of patients 
with a positive pre-treatment culture increase the potential for bias, two factors that are 
likely common in cohorts comprised of people living with HIV. Investigators reporting 
on patients with comorbidities or other factors known to predict early death or LTFU 
should report whether these early events manifest in their cohort and the pre-treatment 
culture status of such patients. 
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Two circumstances must be at play in order for relative measures to differ in the presence 
of selection bias from baseline culture definitions extending past treatment initiation. 
First, a sizable proportion of the cohort must be missing a pre-treatment culture and die or 
be LTFU in the allowable post-treatment initiation collection interval. Second, the 
predictor must be highly associated with both missingness and early death or LTFU. That 
is, the majority of patients missing a pre-treatment initiation culture who die or are LTFU 
must be concentrated within one level of the predictor. If these patients are equally 
distributed between levels of the predictor, no bias will be introduced into the relative 
risk estimate. In the endTB cohort, we found little meaningful change that would affect 
study interpretation of relative measures because, although 12% of the cohort was 
missing a pre-treatment culture, missingness was not highly associated with early death 
and LTFU. The largest shifts in point estimates across baseline culture definitions were 
observed for HIV and CD4 count <200 cells/mm3. This is a logical finding, given HIV 
coinfection and the immune status of people living with HIV are highly predictive of 
mortality.(78,79) The magnitude and direction of selection bias for relative measures has 
been studied extensively, both through simulation using directed acyclic graphs and 
applied within a variety of subject areas.(62,63,80–82) Concordant with our findings, 
these studies also reveal that the magnitude of missingness alone is insufficient to infer 
whether there is bias. It also depends on the proportion of those with the outcome among 
those with missing data.  
Investigators may be tempted to extend the allowable baseline culture collection interval 
past treatment initiation in order to capture more patients, thereby improving study 
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precision. However, in our analysis we observed no improvements in precision despite 
the addition of 6% of the original cohort to analyses extending the culture collection 
interval 30 days past treatment initiation. A precision advantage may be observed when 
adding a relatively large proportion of the total cohort to the analysis, especially in a 
smaller cohort(83). However, the addition of a large proportion of the sample may 
increase the probability of bias, as demonstrated by our simulation findings in which 
overestimates of conversion were larger in cohorts with more missingness of pre-
treatment cultures.  
Several steps can be taken to prevent and assess the potential for this bias. In the analytic 
phase, investigators could implement baseline culture definitions that do not extend the 
allowable collection interval after treatment initiation. While this definition may exclude 
some patients who had a culture shortly after treatment initiation, it also eliminates the 
potential for bias. If investigators extend the culture collection interval definition past 
treatment initiation, the investigator can simply check for death or LTFU events that 
occurred in the post-treatment initiation interval among those without a pre-treatment 
culture. If these events occurred, an investigator should consider how these events were 
distributed across the predictor or treatment of interest and to what extent excluding these 
patients will introduce selection bias into the final estimate. During the data collection 
phase, investigators can avoid the potential for bias altogether by making dedicated 
efforts to collect sputum specimens before or on the day of treatment initiation. But, 
securing complete pre-treatment culture data is undoubtedly difficult in the context of 
observational DR-TB treatment cohorts. Patients may have difficulty producing sputum 
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and operational challenges to obtaining a sputum specimen, such as few laboratories 
equipped to conduct culture testing, impose barriers having pre-treatment culture results. 
Additionally, priority has been placed on decentralized capacity for rapid molecular tests 
(e.g. Xpert® MTB/RIF (Cepheid, Sunnyvale, USA)) to diagnose pulmonary TB and 
detect rifampin resistance, which was recommended by the WHO in 2020.(84) This may 
reduce availability of (pre-treatment) sputum culture results.  
We present potential bias estimates for the proportion with culture conversion 
disaggregated by each of the 17 enrollment sites in order to highlight heterogeneity that 
may arise from settings of different patient characteristics (e.g. comorbidities) and early 
treatment outcomes. Some countries had relatively small sample sizes. In these small sub-
cohorts, even a few patients with a missing pre-treatment culture who die or are LTFU 
early in treatment can impose substantial bias in the proportion with culture conversion. 
Small sample sizes at these sites are not necessarily a study limitation. In fact, they reflect 
the size of cohorts routinely reported on the MDR-TB literature: approximately 8% of 
MDR-TB cohort studies in the last five years reported on less than 25 patients and 31% 
reported on less than 100.(72) Second, in the endTB absolute proportion analysis, we 
calculate the proportion with culture conversion assuming maximum bias by adding to 
the denominator 17 patients who were missing a pre-treatment culture and died or were 
LTFU during the 30-day interval after treatment initiation. An additional 154 patients 
missing a pre-treatment culture were retained during this same period. We did not pursue 
in-depth analyses to assess how the exclusion of retained patients affected the observed 
proportion. Rather, we assume patients with a missing pre-treatment culture convert at an 
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equal or lower frequency than those with a pre-treatment culture because our aim was to 
quantify the upper bound of bias (i.e. overestimates) in the proportion with culture 
conversion.  
The implications of our study findings underscore the need to scrutinize whether bias is 
introduced when determining who is included and excluded from analyses with culture-
based endpoints. Avoiding extension of the baseline culture collection interval past 
treatment initiation will eliminate the potential for bias. When this definition is extended 
past treatment initiation, the decision to do so should be clearly reported and early death 
and LTFU events among excluded patients should be enumerated. Taking these steps will 
improve transparency and comparability of study findings across cohorts, thereby 
improving the evidence based used to inform the treatment of the estimated 500,000 new 




3.5 Tables and Figures 
Table 3.1 Parameters and values, simulation study of bias due to early death and loss-to-follow up events occurring 
during a hypothetical post-treatment initiation sputum collection interval among participants missing a pre-treatment 
sputum culture 
Parameter Description Simulated values 
Culture positivetruth (Pt) 
Proportion of patients who would have been observed to be culture 
positive at the time of treatment initiation, had they had a sputum 
culture result 
60% to 90% by 10% 
Culture missingobserved, (m) Proportion of patients observed missing a pre-treatment culture  0% to 30% by 5% 
Culture positivetruth│Culture 
missingobserved (Pt│m)  
Proportion of patients with a missing pre-treatment culture who 
would have been observed to have a positive culture at treatment 
initiation, had they had a culture 




Proportion of patients with conversion among patients who would 
have been observed to have a positive culture at the time of 
treatment initiation, had they had a sputum culture result 
50% to 90% by 20% 
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Figure 3.1 Culture conversion and early death and loss-to-follow up events among 
participants missing a pre-treatment culture, simulation study of cohort where 
Pt=70%,  Pt│m=50%, and C│Pt=70% 
 
Legend: Figure represents a simulated cohort of patients in which: 1) 70% are truly 
culture positive, 2) Of patients missing a culture, 50% are truly culture positive and 50% 
are truly culture negative, and 3) among truly culture-positive patients, 70% achieved 
culture conversion. If 20% (x-axis=0.20) of patients were missing their pre-treatment 
culture and 100% of these patients died or were LTFU during the hypothetical post-
treatment initiation sputum collection interval, the observed proportion with culture 
conversion would be 82% (■), a 12 percentage point discrepancy. If 65% (i.e. the 
 
47 
halfway point of the shaded region) died or were LTFU, the reported proportion would be 
76% (▲), a 6 percentage point discrepancy. If 30% died or were LTFU (i.e. the point at 
which conversion rates in patients missing a pre-treatment culture and patients observed 
to have a pre-treatment culture are equal), the reported proportion would be 70% (●), no 
discrepancy. The shaded region can be interpreted similarly in Figures 2-4.  
 
Abbreviations: Loss to follow up (LTFU); Culture positivetruth (Pt); Culture 




Figure 3.2  Culture conversion and early death and loss-to-follow up events among 
participants missing a pre-treatment culture, simulation study of cohort where 
Pt=70%, Pt│m=50%, and C│Pt=50%, 70%, or 90% 
 
Legend: In cohorts with high rates of culture conversion (e.g. 90% conversion in blue), 
there a modest number of patients can be missing a pre-treatment culture (e.g. 15% at 
90% conversion), assuming missing a pre-treatment culture is perfectly correlated with 
death or LTFU (upper bound of shaded region).
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Figure 3.3 Culture conversion and early death and loss-to-follow up events among 
participants missing a pre-treatment culture, simulation study of cohort where Pt 
varies from 60% to 90%, Pt│m=50%, and C│Pt=50%, 70%, or 90%  
 
Legend: As the proportion of patients who are culture positive at treatment initiation 
increases (each panel), the potential magnitude of bias decreases (shared regions become 
smaller). This is because, assuming the proportion missing a pre-treatment culture who 
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are culture positive is held constant (here, 50%), the exclusion of the same number of 
patients from a smaller cohort (i.e. smaller denominator) is more influential on the 




Figure 3.4 Culture conversion and early death and loss-to-follow up events among 
participants missing a pre-treatment culture, simulation study of cohort where 
Pt=70%, Pt│m varies from 250-100% and C│Pt=50%, 70%, or 90%  
 
Legend: 
The maximum magnitude of bias (top of each shaded region) is dependent on the 
proportion of patients who are culture positive among those missing a pre-treatment 
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culture (each panel). If no patients (0%) missing a pre-treatment culture are culture 
positive, then these patients would be excluded from the analysis and no bias will be 
introduced (top left). Conversely, if all (100%) patients missing a pre-treatment culture 
are culture positive, then these patients should be included and the most potential for bias 




Table 3.2 Pre-treatment initiation culture status of participants in the endTB 
observational cohort (N=2790) 
Country 
 -90/+0 days 
Participants 
enrolled, N 
Positive culture  
(-90/+0),  
n (%) 
Negative culture  
(-90/+0),  
n (%) 
Missing culture (m) 
(-90/+0),  
n (%) 
Armenia 107 86 (0.80) 14 (0.13) 7 (0.07) 
Bangladesh 280 187 (0.67) 68 (0.24) 25 (0.09) 
Belarus 109 73 (0.67) 3 (0.03) 33 (0.30) 
Ethiopia 79 34 (0.43) 24 (0.30) 21 (0.27) 
Georgia 291 214 (0.74) 58 (0.20) 19 (0.07) 
Haiti 37 24 (0.65) 2 (0.05) 11 (0.30) 
Indonesia 72 40 (0.56) 8 (0.11) 24 (0.33) 
Kazakhstan 672 418 (0.62) 226 (0.34) 28 (0.04) 
Kenya 7 3 (0.43) 2 (0.29) 2 (0.29) 
Kyrgyzstan 18 13 (0.72) 1 (0.06) 4 (0.22) 
Lesotho 264 127 (0.48) 53 (0.20) 84 (0.32) 
Myanmar 50 16 (0.32) 14 (0.28) 20 (0.40) 
North Korea 155 80 (0.52) 41 (0.26) 34 (0.22) 
Pakistan 302 246 (0.81) 46 (0.15) 10 (0.03) 
Peru 266 158 (0.59) 105 (0.39) 3 (0.01) 
South Africa 49 26 (0.53) 9 (0.18) 14 (0.29) 
Vietnam 32 27 (0.84) 5 (0.16) 0 (0) 





Table 3.3 Sputum culture conversion and early death and loss-to-follow up events among participants missing a sputum 
culture in the specified interval before (-) and after (+) treatment initiation, endTB observational cohort 
Country 
 -90/+0 days -90/+30 days -90/+60 days -90/+90 days 
C│POa, 
 n/N (%) 
C│POa, 

















Armenia 56/86 (0.65) 56/89 (0.63) 1 56/89 (0.63) 1 56/89 (0.63) 1 
Bangladesh 182/187 (0.97) 189/194 (0.97) 0 192/197 (0.97) 0 193/198 (0.97) 0 
Belarus 60/73 (0.82) 74/88 (0.84) 0 82/96 (0.85) 0 83/97 (0.86) 0 
Ethiopia 29/34 (0.85) 33/39 (0.85) 0 33/39 (0.85) 0 33/39 (0.85) 0 
Georgia 188/214 (0.88) 195/221 (0.88) 0 198/225 (0.88) 0 198/225 (0.88) 0 
Haiti 16/24 (0.67) 17/25 (0.68) 0 17/26 (0.65) 0 17/26 (0.65) 0 
Indonesia 27/40 (0.68) 33/48 (0.69) 4 33/50 (0.66) 4 33/51 (0.65) 5 
Kazakhstan 400/418 (0.96) 414/433 (0.96) 1 419/440 (0.95) 1 421/442 (0.95) 1 
Kenya 1/3 (0.33) 2/4 (0.50) 0 2/4 (0.50) 1 2/4 (0.50) 1 
Kyrgyzstan 10/13 (0.77) 12/15 (0.80) 0 12/15 (0.80) 0 12/15 (0.80) 0 
Lesotho 90/127 (0.71) 108/150 (0.72) 8 111/155 (0.72) 10 111/155 (0.72) 10 




North Koreab 42/77 (0.55) 49/87 (0.56) 2 49/87 (0.56) 5 49/87 (0.56) 5 
Pakistan 207/246 (0.84) 209/249 (0.84) 1 210/250 (0.84) 1 210/250 (0.84) 2 
Peru 146/158 (0.92) 153/166 (0.92) 0 153/166 (0.92) 0 153/166 (0.92) 0 
South Africa 25/26 (0.96) 29/30 (0.97) 0 29/30 (0.97) 0 30/31 (0.97) 0 
Vietnam 25/27 (0.93) 26/28 (0.93) 0 26/28 (0.93) 0 26/28 (0.93) 0 
Total 1518/1769 (0.86) 1614/1883 (0.86) 17 1638/1915 (0.86) 24 1644/1922 (0.86) 26 
Abbreviations: Lost to follow up (LTFU), Culture missingobserved, (m); Converted│Culture positiveobserved (C│PO)  








Figure 3.5 Absolute proportion of sputum culture conversion in the endTB observational cohort, by site and allowable 
baseline sputum culture collection interval before (-) and after (+) treatment initiation 
 
*Proportion of the cohort with sputum culture conversion, assuming maximum bias (%	$%&'()*(+│$- +!"#$%&') was 
calculated as follows: (	*+,-./0.1(	*2302/.	4+'%0%-.!"#$%&$'				5			(	1%.1	+/	6789│*2302/.	;%''%,<!"#$%&$'
. 
Legend: Sites on the green line indicate no deaths or LTFU events among participants with a missing culture occurred in the 
specified interval before (-) and after (+) treatment initiation. 
Abbreviations: Armenia (AM), Bangladesh (BD), Belarus (BY), Ethiopia (ET), Georgia (GE), Haiti (HT), Indonesia (ID), 
Kazakhstan (KZ), Kenya (KE), Kyrgyzstan (KG), Lesotho (LS), Myanmar (MM), North Korea (KP), Pakistan (PK), Peru 
(PE), South Africa (ZA), Vietnam (VD) 
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Figure 3.6 Crude relative risk of sputum culture conversion by baseline 
characteristics, comparison extending the interval 30 days past treatment initiation 




Figure 3.7 Crude relative risk of sputum culture conversion by baseline 
characteristics, comparison extending the interval 60 days past treatment initiation 




Figure 3.8 Crude relative risk of sputum culture conversion by baseline characteristics, 
comparison extending the interval 90 days past treatment initiation to no extension of 




Table 3.4 Bias and precision in the relative risk of sputum culture conversion, 
comparison extending the interval 30 days past treatment initiation to no extension 






% biasa MSE 
Diabetes mellitus or glucose intolerance 
-90/+0 days 1687 1.04 (0.99, 1.09) 0 0.001 
-90/+30 days, observed 1795 1.04 (0.99, 1.08) -0.327 0.001 
-90/+30 days, assuming maximum 
bias 
1804 1.03 (0.98, 1.07) -1.371 0.001 
Poorly controlled diabetes (HbA1c >8.0%) 
-90/+0 days 861 1.08 (1.01, 1.15) 0 0.001 
-90/+30 days, observed 905 1.08 (1.02, 1.15) 0.391 0.001 
-90/+30 days, assuming maximum 
bias 
912 1.07 (1, 1.14) -1.117 0.001 
HIV infection 
-90/+0 days 1690 0.83 (0.76, 0.91) 0 0.002 
-90/+30 days, observed 1794 0.85 (0.79, 0.92) 2.257 0.002 
-90/+30 days, assuming maximum 
bias 
1809 0.82 (0.76, 0.89) -1.517 0.002 
CD4 cell count <200 cells/mL 
-90/+0 days 155 1.12 (0.92, 1.35) 0 0.009 
-90/+30 days, observed 181 1.11 (0.94, 1.31) -0.512 0.007 
-90/+30 days, assuming maximum 
bias 
187 1.07 (0.9, 1.27) -4.515 0.01 
Hepatitis B virus infection 
-90/+0 days 1703 1.06 (0.99, 1.13) 0 0.001 
-90/+30 days, observed 1812 1.05 (0.97, 1.12) -1.028 0.001 
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-90/+30 days, assuming maximum 
bias 
1821 1.05 (0.98, 1.13) -0.514 0.001 
Hepatitis C virus infection 
-90/+0 days 1730 0.93 (0.87, 0.99) 0 0.001 
-90/+30 days, observed 1841 0.94 (0.88, 1) 0.924 0.001 
-90/+30 days, assuming maximum 
bias 
1852 0.94 (0.88, 1) 1.107 0.001 
Prior TB treatment with second-line drugs 
-90/+0 days 1496 1.11 (1.05, 1.18) 0 0.001 
-90/+30 days, observed 1590 1.1 (1.04, 1.17) -0.664 0.001 
-90/+30 days, assuming maximum 
bias 
1599 1.11 (1.05, 1.18) 0.119 0.001 
Bilateral disease 
-90/+0 days 1519 0.95 (0.92, 0.99) 0 0 
-90/+30 days, observed 1604 0.95 (0.92, 0.99) -0.012 0 
-90/+30 days, assuming maximum 
bias 
1615 0.95 (0.92, 0.99) -0.393 0 
Cavitary disease 
-90/+0 days 1489 1 (0.96, 1.04) 0 0 
-90/+30 days, observed 1571 1 (0.96, 1.04) -0.318 0 
-90/+30 days, assuming maximum 
bias 
1579 1.01 (0.97, 1.05) 0.574 0 
BMI <18.5 
-90/+0 days 1745 0.91 (0.88, 0.95) 0 0 
-90/+30 days, observed 1853 0.92 (0.88, 0.95) 0.335 0 
-90/+30 days, assuming maximum 
bias 







Table 3.5 Bias and precision in the relative risk of sputum culture conversion, 
comparison extending the interval 60 days past treatment initiation to no extension 






% biasa MSE 
Diabetes mellitus or glucose intolerance 
-90/+0 days 1687 1.04 (0.99, 1.09) 0 0.001 
-90/+60 days, observed 1827 1.04 (0.99, 1.08) -0.357 0.001 
-90/+60 days, assuming maximum bias 1839 1.03 (0.98, 1.08) -1.202 0.001 
Poorly controlled diabetes (HbA1c >8.0%) 
-90/+0 days 861 1.08 (1.01, 1.15) 0 0.001 
-90/+60 days, observed 916 1.09 (1.02, 1.15) 0.745 0.001 
-90/+60 days, assuming maximum bias 923 1.07 (1, 1.15) -0.777 0.001 
HIV infection 
-90/+0 days 1690 0.83 (0.76, 0.91) 0 0.002 
-90/+60 days, observed 1826 0.86 (0.79, 0.93) 2.837 0.002 
-90/+60 days, assuming maximum bias 1845 0.82 (0.76, 0.89) -1.103 0.002 
CD4 cell count <200 cells/mL 
-90/+0 days 155 1.12 (0.92, 1.35) 0 0.009 
-90/+60 days, observed 185 1.1 (0.93, 1.3) -1.455 0.007 
-90/+60 days, assuming maximum bias 192 1.05 (0.88, 1.25) -6.21 0.012 
Hepatitis B virus infection 
-90/+0 days 1703 1.06 (0.99, 1.13) 0 0.001 
-90/+60 days, observed 1844 1.04 (0.96, 1.12) -2.074 0.002 
-90/+60 days, assuming maximum bias 1857 1.04 (0.97, 1.12) -1.353 0.002 
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Hepatitis C virus infection 
-90/+0 days 1730 0.93 (0.87, 0.99) 0 0.001 
-90/+60 days, observed 1873 0.94 (0.88, 1) 0.625 0.001 
-90/+60 days, assuming maximum bias 1887 0.94 (0.88, 1) 0.992 0.001 
Prior TB treatment with second-line drugs 
-90/+0 days 1496 1.11 (1.05, 1.18) 0 0.001 
-90/+60 days, observed 1615 1.1 (1.04, 1.16) -1.015 0.001 
-90/+60 days, assuming maximum bias 1627 1.11 (1.05, 1.18) 0.277 0.001 
Bilateral disease 
-90/+0 days 1519 0.95 (0.92, 0.99) 0 0 
-90/+60 days, observed 1630 0.95 (0.92, 0.99) -0.272 0 
-90/+60 days, assuming maximum bias 1643 0.95 (0.92, 0.99) -0.526 0 
Cavitary disease 
-90/+0 days 1489 1 (0.96, 1.04) 0 0 
-90/+60 days, observed 1595 1 (0.96, 1.03) -0.351 0 
-90/+60 days, assuming maximum bias 1605 1.01 (0.97, 1.05) 0.615 0 
BMI <18.5 
-90/+0 days 1745 0.91 (0.88, 0.95) 0 0 
-90/+60 days, observed 1883 0.92 (0.88, 0.95) 0.21 0 







Table 3.6 Bias and precision in the relative risk of sputum culture conversion, 
comparison extending the interval 90 days past treatment initiation to no extension 






% biasa MSE 
Diabetes mellitus or glucose intolerance 
-90/+0 days 1687 1.04 (0.99, 1.09) 0 0.001 
-90/+90 days, observed 1834 1.03 (0.99, 1.08) -0.76 0.001 
-90/+90 days, assuming maximum bias 1848 1.02 (0.98, 1.07) -1.471 0.001 
Poorly controlled diabetes (HbA1c >8.0%) 
-90/+0 days 861 1.08 (1.01, 1.15) 0 0.001 
-90/+90 days, observed 918 1.08 (1.01, 1.15) -0.346 0.001 
-90/+90 days, assuming maximum bias 926 1.06 (0.99, 1.14) -1.712 0.002 
HIV infection 
-90/+0 days 1690 0.83 (0.76, 0.91) 0 0.002 
-90/+90 days, observed 1833 0.85 (0.79, 0.92) 2.479 0.002 
-90/+90 days, assuming maximum bias 1854 0.82 (0.76, 0.89) -1.288 0.002 
CD4 cell count <200 cells/mL 
-90/+0 days 155 1.12 (0.92, 1.35) 0 0.009 
-90/+90 days, observed 186 1.1 (0.93, 1.29) -1.881 0.007 
-90/+90 days, assuming maximum bias 193 1.04 (0.88, 1.24) -6.627 0.012 
Hepatitis B virus infection 
-90/+0 days 1703 1.06 (0.99, 1.13) 0 0.001 
-90/+90 days, observed 1851 1.04 (0.96, 1.12) -1.926 0.002 
-90/+90 days, assuming maximum bias 1865 1.05 (0.97, 1.13) -1.151 0.002 
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Hepatitis C virus infection 
-90/+0 days 1730 0.93 (0.87, 0.99) 0 0.001 
-90/+90 days, observed 1880 0.94 (0.88, 1) 0.634 0.001 
-90/+90 days, assuming maximum bias 1895 0.94 (0.88, 1) 1.059 0.001 
Prior TB treatment with second-line drugs 
-90/+0 days 1496 1.11 (1.05, 1.18) 0 0.001 
-90/+90 days, observed 1621 1.1 (1.04, 1.16) -1.038 0.001 
-90/+90 days, assuming maximum bias 1634 1.11 (1.05, 1.18) 0.177 0.001 
Bilateral disease 
-90/+0 days 1519 0.95 (0.92, 0.99) 0 0 
-90/+90 days, observed 1637 0.95 (0.92, 0.99) -0.346 0 
-90/+90 days, assuming maximum bias 1652 0.95 (0.91, 0.98) -0.769 0 
Cavitary disease 
-90/+0 days 1489 1 (0.96, 1.04) 0 0 
-90/+90 days, observed 1602 1 (0.96, 1.03) -0.514 0 
-90/+90 days, assuming maximum bias 1614 1 (0.96, 1.04) 0.251 0 
BMI <18.5 
-90/+0 days 1745 0.91 (0.88, 0.95) 0 0 
-90/+90 days, observed 1890 0.92 (0.88, 0.95) 0.136 0 







4 COMPARATIVE EFFECTIVENESS STUDIES OF TIME-VARYING 




Conventional, longer regimens used to treat MDR-TB are administered for up to 24 
months and are often individualized to patient characteristics at treatment initiation. 
These baseline patient characteristics used to determine the initial treatment regimen may 
also be associated with the outcome, a common source of bias in observational cohort 
studies known as confounding.(85) Regimens can also change over the course of 
treatment based on patients’ evolving clinical status. Consequently, MDR-TB treatment 
is, for many patients, a time-varying exposure.(9) Time-varying treatments can be subject 
to treatment-confounder feedback, known as time-dependent confounding affected by 
previous exposure.(41,86) Time-dependent confounding occurs when a time-varying 
factor is associated with the outcome, predicts subsequent treatment, and is affected by 
past treatment. For example, the regimen administered at treatment initiation, referred to 
as “baseline”, is often individualized based on comorbidities, such as HIV, and extent of 
drug resistance. A provider may subsequently change the baseline regimen based on 
time-varying factors, such as development of further drug resistance or lack of 
microbiological improvement (i.e. conversion of sputum smear and culture). These time-
varying factors strongly predict treatment outcome and are affected themselves by 
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previous treatment.(42) Methods to control for time-dependent confounding include 
inverse probability weighting in marginal structural models, the g-formula, and structural 
nested models.(19,41) Based on a 2020 systematic search for longitudinal studies of TB 
treatment cohorts using these methods to adjust for time-dependent confounding, we 
identified that none of these methods have been applied to TB-focused research 
questions.(42)  
Since most observational analyses of MDR-TB treatment classify patients’ regimens only 
according to their composition at treatment initiation (baseline), regardless of whether 
treatment changed over the course of follow up, they fail to account for the fact that 
MDR-TB treatment is time-varying. Comparative effectiveness analyses using baseline 
treatment definitions produce estimates of the observational analogue of the intention-to-
treat effect, that is, the effect of initiating a particular drug or regimen. Often, of greater 
policy and clinical interest is the observational analogue of the per-protocol effect, which 
estimates the effect of initiating and completing a treatment course with a particular drug 
or regimen for its intended duration.(81,87,88) In fact, many of the priority research 
questions identified by WHO in the 2019 MDR-TB treatment guidelines focus on 
regimen composition and length of treatment,(61) highlighting the importance of 
estimating per-protocol effects.  
Analyses of the per-protocol analogue have the added challenge of adjustment for time-
dependent confounding. One method to estimate per-protocol effects and control for 
time-dependent confounding is to artificially censor patients’ follow up time when their 
treatment deviates from the treatment administered at baseline and use inverse probability 
 
68 
of censoring weights to adjust for selection bias due to artificial censoring. Through 
weighting, this approach creates a pseudo-population where all individuals complete their 
initial treatment and where time-varying treatment and time-varying confounders are no 
longer associated.(43) However, in order to implement this analytic approach, time-
varying data on predictors of treatment regimen changes must be measured. To date, few 
cohorts have collected the extent of longitudinal data need to adjust for bias, precluding 
the ability to estimate per-protocol effects in the observational context. When data are 
available to conduct both the intention-to-treat and per-protocol analogue, investigators 
should pursue analyses that produce estimates of both and compare findings. Differences 
between the analyses are dependent on the extent of protocol deviations (e.g. treatment 
regimen changes in MDR-TB cohorts). When deviations are rare, differences between 
analyses are likely to be minimal. Conversely, differences may be larger when deviations 
are common and can provide insight into the presence of time-dependent confounding.  
In Aim 1, we applied the aforementioned artificial censoring approach to answer the 
research question of whether adding delamanid to an MDR-TB regimen comprised of 
only three drugs likely to be effective provided a benefit on two- and six-month sputum 
culture conversion. Here, for this same research question, we (1) compare weighted and 
unweighted models estimating the per-protocol analogue to assess the impact of selection 
bias (and, by extension, of time-dependent confounding) and (2) assess whether estimates 






4.2.1 Data source, study population, and definitions 
We used the same data source and study population as in Aim 1. In brief, we included a 
subset of participants from the endTB observational cohort who had a positive baseline 
sputum culture and received one of the following baseline MDR-TB regimens of interest: 
(1) “delamanid-containing” regimens comprised of delamanid plus a background regimen 
of three drugs likely to be effective, (2) “delamanid-free” regimens comprised of three 
drugs likely to be effective, none of which was delamanid. We assessed the relative risk 
and risk difference of two- and six-month culture conversion across groups using the 
same outcomes definitions described in Aim 1. 
4.2.2 Marginal versus conditional effects 
In order to make comparisons across models producing estimates with analogous 
interpretations, we divide results by whether the selected model produces estimates of 
marginal or conditional effects.  Marginal models produce estimates of the average effect 
at the population level of moving the population from unexposed to exposed. Conditional 
models produce estimates of average effect that are relevant within strata defined by a set 
of baseline covariates.(89)  
4.2.2.1 Descriptive analysis of the distribution of censoring 
To investigate the degree to which exposure varied over time, we assessed the 
distribution of censoring in the data according to baseline exposure group and each 
outcome. We additionally calculated crude relative risks to identify the association 
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between censoring and the exposure (delamanid-containing regimens) and each outcome 
using the following formula, where C=1 represents the number of participants censored 







4.2.3 Inverse probability censoring weighted analysis of the per-protocol analogue 
We used the censoring approach described at length in Aim 1 to estimate the per-protocol 
analogue. This analysis produces an estimate of the per-protocol analogue representing 
the effect of initiating an intervention and maintaining the intervention for a protocol-
defined duration. In brief, we artificially censored participants if the addition or 
subtraction of a drug resulted in an exposure group switch lasting >2 weeks. Artificial 
censoring will introduce selection bias, which must be controlled for via inverse 
probability of censoring weights. To calculate inverse probability of censoring weights, 
we fitted a pooled logistic regression to estimate the probability that the participant was 
not censored (i.e. that their initial exposure group would be sustained, conditional on 
time-varying predictors of changing treatment). We calculated weights by multiplying the 
probability of being uncensored across each time point. Control for baseline confounders 
of treatment differed, dependent on whether the intention was to estimate marginal 
(Section 4.2.3.1) or conditional effects (Section 4.2.3.2). 
Only participants whose initial treatment was unchanged (i.e. uncensored participants) 
were included in the final logistic model with their associated weights. Using the same 
sub-cohort of uncensored participants, we compared estimates from models that control 
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(weighted analysis) versus those that do not control (unweighted analysis) for selection 
bias and, by extension, time-dependent confounding. We qualitatively describe the 
difference between these estimates. 
4.2.3.1 Marginal effects of the censoring weighted per-protocol analogue 
We used composite inverse probability of treatment weights and inverse probability of 
censoring weights to estimate the marginal average treatment effect of delamanid-
containing regimens versus delamanid-free regimens. 
To calculate inverse probability of treatment weights, all participants were assigned a 
time-fixed weight defined as the inverse of the probability of receiving the treatment 
actually received conditional on baseline confounders of treatment. Through content 
knowledge and directed acyclic graphs, we selected confounders and fitted multiple 
baseline adjusted models, as described in Aim 1, Appendix 5.4. We selected a final 
baseline model comprised of age, sex, whether the participant was in the hospital at 
treatment initiation, the number of Group A drugs in the regimen, whether the patient was 
on imipenem-cilastatin, body mass index <18.5, HIV infection, and hepatitis C infection. 
The following formula represents the unstabilized treatment weight (WA) for exposed 
participants, where A is the baseline exposure group (1=delamanid-containing, 
0=delamanid-free) and L is the vector of baseline covariates: WA = 
+
12	[4*+│6]. For 
unexposed participants, WA is represented as WA = 
+
+(12	[4*+│6]. Inverse probability of 
treatment weighting creates a pseudopopulation where treatment and confounders are 
unrelated to each other.  
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Inverse probability of censoring weights, described in Section 4.2.3 and treatment 
weights were multiplied together to calculate a composite weight, as represented by the 
formula WC (t) =  ∏ +
128%(') = 09*, *,('),			%(' − 1) = 0,			/: 	×	12</ = 1=*>
?
@*/ 	 for 
exposed participants and ∏ +
128%(') = 09*, *,('),			%(' − 1) = 0,			/: 	×	+(12</ = 1=*>
?
@*/ 	  
for unexposed participants. We fitted a second logistic regression model including 
uncensored participants weighted by their composite weight. From this model, we 
calculated the predicted probabilities of two- and six-month culture conversion for each 
participant. Then, we computed the mean predicted probability by exposure group, and 
used the probabilities of conversion by exposure group to calculate the relative risk and 
risk difference.(90) Confidence intervals were estimated using nonparametric 
bootstrapping with 500 samples.  
4.2.3.2 Conditional effects of the censoring weighted per-protocol analogue 
To estimate conditional effects of the per-protocol analogue, we applied inverse 
probability of censoring weights to uncensored participants in a second logistic 
regression model and directly adjusted for baseline confounders in the model. This direct 
baseline adjustment method is in contrast to the inclusion of inverse probability of 
treatment weights used in the marginal model. Relative risks and risk differences were 
calculated using the mean predicted probability and nonparametric bootstrapping.(90) 
4.2.4 Baseline-adjusted analysis of the intention-to-treat analogue 
The observational analogue of the intention-to-treat effect estimates the effect of 
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initiating an intervention and does not account for post-baseline changes in treatment. 
Thus, we classified participants according to the treatment they had received at baseline 
(defined as day 7 of treatment) and adjusted for baseline confounders of treatment using 
several methods, described here in Section 4.2.4.1 and Section 4.2.4.2:  
4.2.4.1 Marginal effects of the baseline-adjusted intention-to-treat analogue 
For marginal effects of the intention-to-treat analogue, we estimated baseline treatment 
weights using the same approach described in Section 4.2.3.1 above. We fitted a 
weighted logistic regression model with culture conversion as the dependent variable, 
treatment group as the independent variable and treatment weights WA.  
4.2.4.2 Conditional effects of the baseline-adjusted intention-to-treat analogue 
We used logistic regression and log binomial regression to estimate conditional effects of 
the intention-to-treat analogue. Both regression methods produce estimates of the 
association of treatment and the outcome within levels of the baseline confounders in the 
model.  
We fitted a logistic regression model on baseline confounders and estimated risks of 
conversion by exposure group using the predicted probabilities from the model and 
nonparametric bootstrapping to estimate confidence intervals.(90) The log binomial 
model directly estimates relative risks,(91) thus indirect estimation of risks was not 






4.3.1  Inverse probability censoring weighted analysis of the per-protocol analogue 
Analyses of the per-protocol analogue include 349 participants: 10 participants were 
excluded for missing time-varying data, two for missing both time-varying data and 
baseline data, and two for missing baseline data (Table 4.1).  
4.3.1.1 Distribution of censoring 
As reported in Aim 1, 97 (27%) participants were artificially censored because their 
regimen was changed such that it resulted in an exposure group switch for more than two 
weeks. Censoring occurred at a median of 11 weeks (25th percentile=5 weeks, 75th 
percentile=17 weeks). Censored participants were proportionally represented within their 
respective baseline exposure groups (28.8% censored in delamanid-containing, 25.6% 
censored in delamanid-free) (Table 4.2). Receiving a delamanid-containing regimen was 
not strongly associated with changing exposure groups (i.e. censoring) (crude RR: 1.12 
(95% CI: 0.79, 1.60) (Table 4.3). Participants who converted were less likely to have 
changed exposure groups (i.e. be censored) than those who did not experience conversion 
(crude RR at two months: 0.63 (95% CI: 0.45, 0.89); crude RR at six months: 0.66 (95% 
CI: 0.44, 0.98)) (Table 4.3). 
4.3.1.2 Marginal effects of the censoring weighted per-protocol analogue 
Using composite inverse probability of treatment and censoring weights resulted in a 
relative risk of conversion at two months of 0.93 (95% CI: 0.52, 2.36) and 0.90 (95% CI: 
0.56, 1.76) at six months (Table 4.1, Model 3). 
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4.3.1.3 Conditional effects of the censoring weighted per-protocol analogue 
Using inverse probability of censoring weights and adjusting for baseline confounders in 
the final model, participants receiving delamanid had a lower risk of two-month 
conversion, albeit with a confidence interval that included the null (RR: 0.93 (95% CI: 
0.67, 1.41)) (Table 4.1, Model 5). Similar results were observed for six month 
conversion.  
4.3.1.4 Comparison of weighted and unweighted models to assess impact of selection 
bias 
Across models estimating marginal and conditional effects, weighted and unweighted 
point estimates were similar (Table 4.1, Model 2 vs 3 and Model 4 vs 5). Confidence 
intervals from weighted analyses were notably wider than those that omitted the weights. 
Similar results were observed for risk differences. 
4.3.2 Baseline-adjusted intention-to-treat analogue 
Among the subcohort of 363 participants identified in Aim 1, 359 participants had 
complete data on baseline confounders and were included in baseline-adjusted analyses 
of the intention-to-treat analogue (Table 4.1). 
4.3.2.1 Marginal effects of the baseline-adjusted intention-to-treat analogue 
Using inverse probability of treatment weights, participants on delamanid-containing 
regimens had a lower risk of culture conversion at two months when compared to 
participants on delamanid-free regimens (RR: 0.85 (95% CI: 0.66, 1.08), RD: -0.08 (95% 
CI: -0.19, 0.04)) (Table 4.1, Model 6). Estimates for six month culture conversion were 
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slightly attenuated towards the null (RR: 0.88 (95% CI: 0.80, 0.98), RD: -0.10 (95% CI: -
0.17, 0.02)) (Table 4.1, Model 6).  
4.3.2.2 Conditional effects of the baseline-adjusted intention-to-treat analogue 
Using the baseline-adjusted logistic regression approach, the relative risk of culture 
conversion was 0.90 (95% CI: 0.71, 1.13) at two months and 0.93 (95% CI: 0.84, 1.01) at 
six months (Table 4.1, Model 7). The log binomial model yielded similar relative risks, 
with point estimates slightly closer to the null (Table 4.1, Model 8).  
4.3.3 Observational analogue of the intention-to-treat versus per protocol analyses 
Despite fluctuations in point estimates, estimates of the intention-to-treat and per protocol 
analogue consistently yielded similar results. A minor exception to this is that the 
marginal effect of the intention-to-treat analogue (Table 4.1, Model 6) indicated 
participants on delamanid-containing regimens had relatively less conversion than 
participants on delamanid-free regimens by two months (52% vs 56%, RR: 0.85 (95% 
CI: 0.66, 1.08) in comparison to the per-protocol analogue (46% vs 54%, RR: 0.93 (95% 
CI: 0.52, 2.36) (Table 4.1, Model 3). However, the variability around the per-protocol 
analogue estimate was larger. Conditional effects of the intention-to-treat analogue 
(Table 4.1, Models 7 and 8) were nearly identical to that of the per protocol analogue 





Using models accounting for the time-varying nature of MDR-TB treatment did not 
change our conclusion that there was no effect of adding delamanid to MDR-TB 
regimens containing three drugs likely to be effective, despite modest fluctuations in 
point estimates and confidence intervals across models. Estimates of the observational 
analogue of the per-protocol effect and the intention-to-treat effect were similar. Both of 
these findings are likely due to the frequency and distribution of censoring (i.e. exposure 
group changes) in our data for the research question at hand.  
We did not identify a difference between censoring weighted and unweighted per-
protocol analyses. Participants were censored if their exposure group changed, either due 
to the addition or subtraction of delamanid or a drug change that resulted in the 
participant no longer receiving three drugs likely to be effective in the background 
regimen. The likely reason for not identifying differences between these analyses is that 
changes to the primary drug of interest, delamanid, were rare (12/97, 12%). Artificial 
censoring was more common for changes in the background regimen, such that they were 
no longer receiving three background drugs likely to be effective. Importantly, a 
necessary condition for there to be meaningful differences between estimates is that 
censoring be highly associated with the exposure and the outcome.(82,92) We cannot rule 
out that misspecification of the model used to derive censoring weights could explain our 
finding that there were not meaningful differences between weighted and unweighted 
models. However, we tested multiple models with different variable combinations and 
specifications and observed similar results (Appendices 5.2 and 5.3).  
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We also did not identify a clinically meaningful difference between results of standard 
baseline-adjusted models (logistic regression, log binomial regression), which estimate 
the intention-to-treat analogue, and the inverse probability censoring weighted analysis 
estimating the per-protocol analogue. For this particular research question, the effect of 
adding delamanid to a three drug regimen at baseline (i.e. intention-to-treat analogue) is 
similar to that of adding and maintaining delamanid in a three drug regimen for the first 
six months of treatment (i.e. per-protocol analogue). Like that of the weighted and 
unweighted per-protocol analyses, this may be due to the small proportion of participants 
censored and censoring’s distribution across exposure groups and the outcomes.  
Despite our primary finding that results were relatively consistent across various models, 
investigators conducting research with MDR-TB treatment cohorts should still pursue 
analyses that consider the time-varying nature of MDR-TB treatment. This approach is 
particularly important when treatment changes are driven by factors that also impact 
treatment outcome. For example, a research priority highlighted in the 2019 MDR-TB 
guidelines is the optimization of the dose and duration of linezolid.(61) Linezolid is a 
highly active anti-TB drug that often results in significant toxicity.(9,93–97) When 
toxicity occurs, such as the development of myelosuppression or peripheral neuropathy, 
cessation of linezolid is recommended. A comparative safety observational study 
assessing the effect of three months of linezolid versus six months of linezolid on a safety 
endpoint will be biased by the fact that patients receive shorter durations of linezolid 
because of toxicity. In such an analysis, continuation of linezolid for six months would be 
highly associated with the absence of toxicity (the outcome) in previous months. More 
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complex analyses using censoring and weighting techniques are required to control for 
bias.(98)  
The present study highlights some important analytic issues that investigators working 
with MDR-TB treatment cohorts should consider. Baseline adjusted comparative 
effectiveness analyses are the standard in assessing efficacy of MDR-TB treatment 
regimens.(23,58) Depending on the research question, these analyses will not necessarily 
be biased. However, they may not be answering the appropriate clinical question if the 
intention-to-treat analogue is not of greatest interest for decision makers. Rather, if the 
objective is to estimate the per-protocol analogue, the artificial censoring technique 
applied here is a simple way to identify the effect of treatment for a protocolized duration 
while simultaneously resolving the potential for time-dependent confounding.(43) 
Investigators should carefully define the most important research questions, identify the 
exposure groups to be compared, and use an analytic approach that will produce an 
estimate of the causal effect (intention-to-treat or per-protocol) that is intended. When 
possible, investigators can conduct analyses to assess both the intention-to-treat and per-
protocol analogues. Target trial emulation is an intuitive framework to assist investigators 
through these steps.(35,37)  
A critical barrier to conducting analyses that account for treatment changes is the absence 
of data of sufficient quality and granularity. However, a major strength of this study is 
that the endTB cohort is the first longitudinal study of its size to have systematically 
collected prospective data on factors that have otherwise been absent in other 
programmatic cohorts. Through monthly patient encounters and intensive 
 
80 
pharmacovigilance, detailed data on these potential confounders have been collected and 
can be controlled for appropriately. Without such data, analyses accounting for the time-
varying nature of treatment would not be possible. The limitations of this study are those 
that are inherent in using observational data to estimate causal effects. As previously 
noted, we cannot rule out the potential for model misspecification or unmeasured 
confounding; if these occurred, the observed associational estimates would not equate to 
causal effects. However, given that the study could draw from extensive longitudinal data 
and that it produced consistent findings across multiple models, the risk of residual bias 
due to model misspecification and unmeasured confounding is likely low. 
Using the clinical question of adding delamanid to a three drug MDR-TB regimen as a 
guide, we determined, across multiple models with different interpretations, that the 
addition of delamanid did not have a significant effect on culture conversion at either of 
two time points. Treatment regimen changes were largely unrelated to delamanid and did 
not predict culture conversion, which likely explains the consistency of estimates. 
Despite these findings, investigators should still implement analyses that consider the 
time-varying nature of MDR-TB treatment, especially when the clinical question of 
interest involves a treatment that frequently changes and when treatment changes are 




4.5 Tables and Figures 
Table 4.1 Comparison of analyses that assess the effect of adding delamanid to a regimen composed of three drugs 
likely to be effective, endTB observational cohort (N=363) 
Model 
# 
  Two-month culture conversion Six-month culture conversion 
Analysis N RR (95% CI) RD (95% CI) RR (95% CI) RD (95% CI) 
1 Crude 363 0.89 (0.72, 1.09)  -0.06 (-0.17, 0.05) 0.91 (0.82, 1.00) -0.08 (-0.16, -0.00) 
IP censoring weighted (unstabilized), per protocol analogue 
 Marginal effects      
2 Unweighted (biased) 349a 0.90 (0.71, 1.16) -0.06 (-0.19, 0.09) 0.93 (0.82, 1.02) -0.07 (-0.17, 0.01) 
3 Weightedb 349a 0.93 (0.52, 2.36) -0.04 (-0.30, 0.40) 0.90 (0.56, 1.76) -0.09 (-0.42, 0.38) 
 Conditional effects      
4 Unweighted (biased) 349a 0.90 (0.71, 1.13) -0.06 (-0.18, 0.08) 0.92 (0.82, 1.01) -0.07 (-0.16, 0.01) 
5 Weighted 349a 0.93 (0.67, 1.41) -0.04 (-0.20, 0.20) 0.93 (0.78, 1.05) -0.06 (-0.21, 0.05) 
Baseline adjusted, intention-to-treat analogue 
 Marginal effects      
6 IP treatment weighted (unstabilized)d 359




 Conditional effects      
7 Logistic regression 359c 0.90 (0.71, 1.13) -0.05 (-0.17, 0.07) 0.93 (0.84, 1.01) -0.06 (-0.15, 0.01) 
8 Log binomiale 359c 0.92 (0.74, 1.13) - 0.97 (0.87, 1.08) - 
Abbreviations: Inverse probability (IP), risk ratio (RR), risk difference (RD), bedaquiline (BDQ) 
a N=10 participants excluded for missing time-varying data, N=2 participants excluded for missing time-varying and baseline 
data, N=2 participants excluded for missing baseline data 
b Unstabilized IP weight (product of censoring and treatment) mean (minimum, maximum): 2.56 (1.06, 18.6) 
c N=4 participants excluded for missing baseline data 
d Unstabilized IP treatment weight mean (minimum, maximum):  1.96 (1.01, 13.71) 




Table 4.2 Proportion of participants censored, by exposure group and two- and six-month culture conversion in 
analysis to assess the effect of adding delamanid to a regimen composed of three drugs likely to be effective, endTB 
observational cohort (N=363) 
 Delamanid-containing (N=125) Delamanid-free (N=238) 
 Censored  Uncensored Censored Uncensored 
Total, n/N (%) 36/125 (28.8) 89/125 (71.2) 61/238 (25.6) 177/238 (74.4) 
Two-month, converted, n/N (%) 14/36 (38.9) 48/89 (53.9) 27/61 (44.3) 106/177 (59.9) 
Two-month, did not convert, n/N (%) 22/36 (61.1) 41/89 (46.1) 34/61 (55.7) 71/177 (40.1) 
Six-month, converted, n/N (%) 28/36 (77.8) 73/89 (82.0) 50/61 (82.0) 162/177 (91.5) 
Six-month, did not convert, n/N (%) 8/36 (22.2) 16/89 (18.0) 11/61 (18.0) 15/177 (8.5) 
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Table 4.3 Crude association of censoring with exposure group and outcome in 
analysis to assess the effect of adding delamanid to a regimen composed of three 
drugs likely to be effective, endTB observational cohort (N=363) 
Association Risk ratio (95% CI) 
Association between censoring and exposure group 1.12 (0.79, 1.60) 
Association between censoring and two-month conversion 0.63 (0.45, 0.89) 







Appendix 5.1 Target trial protocol and emulation of the target trial using endTB observational cohort data 
Objective: Evaluate the effect of adding delamanid to an MDR-TB regimen that contains 3 likely effective drugs. 
 Target trial Observational analysis 




- Age 14+ 
- Diagnosis of MDR-TB from: 1) a sputum specimen collected no more than 
90 days prior to the date of trial screening with positive growth of M.tb in 
culture and documented phenotypic resistance to rifampin OR 2) a sputum 
specimen collected no more than 90 days prior to the date of trial screening 
with positive growth of M.tb in culture, and a genotypic test  positive for 





Delamanid plus a background regimen of 3 likely effective drugs 
administered for 24 weeks, where a likely effective drug is defined as a drug 
for which resistance testing indicated participants’ M.tb strain was not 
resistant to the drug or a drug for which no resistance testing was conducted 
and the participant had not previously received the drug for ≥1 month 
Comparator 
A regimen of 3 likely effective drugs, none of which are delamanid, 







Randomized Randomization assumed within 
levels of covariates 
Follow up Time zero  
Treatment assignment 
End of follow up 
Outcome, 24 weeks after time zero 
LTFU 
Treatment interruption for ≥2 months 
 
Time zero 
The earliest start date of 
bedaquiline or delamanid 
initiation with endTB 




Outcome Six-month culture conversion, defined as two, consecutive negative cultures 
collected at least 15 days apart, the first occurring before 180 days of 
treatment and the second before 210 days; death and LTFU prior to 180 days 




Intention-to-treat effect Per-protocol effect 
Statistical 
analysis 
Crude ratio and difference of the proportion with two-month and six-month 
culture conversion across arms 
Main effect measure 
Two-month culture conversion risk ratio and risk difference 
Six-month culture conversion risk ratio and risk difference 
Inverse probability censoring 
weights 





Appendix 5.2 Model specification and weight diagnostics for inverse probability of censoring weights 
Model Specification Weight N Mean (SD) Min, max 
1 Numerator includes time (stabilized). Denominator includes 
treatment group, time-varying linear term for # Group A drugs, 
time-varying smear result (+/-), time-varying linear term for # 
SAEs/time, time-varying linear term for # AEs/time, time-
varying term for hospitalization (0/1), baseline age and sex, a 3-
knot spline for time, time. 
Unstabilized 349a 1.35 (0.56) 1.00, 7.25 
Stabilized 349a 0.99 (0.40) 0.75, 5.24 
2b Numerator includes time (stabilized). Denominator includes 
exposure group, time-varying linear term for # Group A drugs, 
time-varying smear result (+/-), time-varying linear term for # 
AEs, time-varying term for hospitalization (0/1), a 3-knot spline 
for time, time. 
Unstabilized 349a 1.34 (0.44) 1.00, 6.40 
Stabilized 349a 0.98 (0.31) 0.76, 4.62 
3 Numerator includes time (stabilized). Denominator includes 
exposure group, time-varying linear term for # Group A drugs, 
time-varying smear result (+/-), time-varying linear term for # 
AEs/time, a 3-knot spline for time, time. 
Unstabilized 349a 1.34 (0.48) 1.00, 7.37 
Stabilized 349a 0.98 (0.34) 0.76, 5.33 
4 Numerator includes time (stabilized). Denominator includes 
exposure group, time-varying linear term for # Group A drugs, 
time-varying linear term for number of SAEs/time, time-varying 
linear term for # AEs/time, time-varying term for hospitalization 
(0/1), baseline age and sex, a 3-knot spline for time, time. 
Unstabilized 359c 1.35 (0.56) 1.00, 7.86 




BDQ Numerator includes time (stabilized). Denominator includes 
exposure group, time-varying linear term for # Group A drugs, 
time-varying smear result (+/-), time-varying linear term for # 
AEs, time-varying term for hospitalization (0/1), a 3-knot spline 
for time, time 
Unstabilized 288d 1.30 (0.35) 1.00, 4.04 
Stabilized 288d 0.98 (0.30) 0.77, 3.02 
Abbreviations: Standard deviation (SD), adverse event (AE), serious adverse event (SAE), Sensitivity analysis restricted to 
participants also receiving bedaquiline (BDQ)  
a N=10 participants excluded for missing time-varying data, N=2 participants excluded for missing baseline and time-varying 
data, N=2 participants excluded for missing baseline data 
b Model used in primary analysis 
c N=7 participants excluded for missing time-varying data N=1 participant excluded for missing baseline data 




Appendix 5.3 Mean predicted probabilities, mean risk ratio, and mean risk difference, by model specification 
Model Weight N Two-month culture conversion Six-month culture conversion 
Mean RR Mean RD Mean RR Mean RD 
1 Unstabilized 349a 0.97 -0.02 0.94 -0.06 
Stabilized 349a 0.97 -0.02 0.94 -0.06 
2b Unstabilized 349a 0.94 -0.04 0.93 -0.06 
Stabilized 349a 0.94 -0.04 0.93 -0.06 
3 Unstabilized 349a 0.93 -0.04 0.93 -0.07 
Stabilized 349a 0.94 -0.04 0.93 -0.07 
4 Unstabilized 359c 1.01 0.01 0.94 -0.05 
Stabilized 359c 1.01 0.01 0.94 -0.05 
BDQ Unstabilized 288d 0.96 -0.02 1.01 0.01 
Stabilized 288d 0.97 -0.02 1.02 0.02 
Abbreviations: Sensitivity analysis restricted to participants also receiving bedaquiline (BDQ) 
a N=10 participants excluded for missing time-varying data, N=2 participants excluded for missing baseline and time-varying data, 
N=2 participants excluded for missing baseline data 
b Model used in primary analysis 
c N=7 participants excluded for missing time-varying data N=1 participant excluded for missing baseline data 










Legend: The structure of bias assumed in Aim 1 is represented by the generalized directed acyclic graph above. We used 
content knowledge to select confounding variables. Baseline confounders used in the primary analysis include age, sex, 
whether the participant was in the hospital at treatment initiation, the number of Group A drugs in the regimen, whether the 
patient was on imipenem-cilastatin, body mass index <18.5, HIV infection, and hepatitis C; time-varying confounders used in 















Appendix 5.5 Model specification for baseline confounders 
We compared multiple models adjusted for baseline confounders. The below table 
indicates the variables included in each model on the corresponding forest plots for two-
month and six-month culture conversion. Shading indicates the variable was included in 
the specified model. 
Covariate 
Model number 
1 2 3 4 5 6 7a 8 
Age, sex         
In hospital at baseline         
# Group A drugs         
Imipenem/cilastatin         
Malnutrition         
HIV         
Hepatitis C         
Cavitation and smear grade ≥ 2++         
 




Two-month culture conversion 
 




Appendix 5.6 Missing indicator analysis for baseline confounders 
In Models 1-7 (Appendix 5.4), only 4/363 patients had missing data (N=2 for body mass index, N=1 for HIV, N=1 for 
Hepatitis C). Models using missing indicator variables for these covariates did not converge. Substantial data were missing for 
the composite variable for cavitary disease and smear grade (N=319/363) (Model 8, Appendix 5.4). We conducted a missing 
indicator analysis for the cavitary disease and smear grade variable following the principles of Greenland.(44) Results were 
nearly identical across analyses excluding the cavitation and smear variable from the model and including a missing indicator.  
Analysis 
Two-month culture conversion Six-month culture conversion 
N RR (95% CI) N RR (95% CI) 
No adjustment for cavitation and smear 359 0.92 (0.75, 1.14) 359 0.97 (0.87, 1.08) 
Exclusion of patients missing data for 
cavitation and smear 319 0.84 (0.65, 1.09) 319 0.96 (0.85, 1.09) 
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